Beyond Meat (BYND) 10-K 1 Mar 22 2021 FY Annual report Financial data

Cover Page Document

Cover Page Document - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2021	Feb. 28, 2022	Jul. 02, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-38879
Entity Registrant Name	BEYOND MEAT, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-4087597
Entity Address, Address Line One	119 Standard Street
Entity Address, City or Town	El Segundo
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90245
City Area Code	866
Local Phone Number	756-4112
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	BYND
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 9.1
Entity Common Stock, Shares Outstanding		63,455,450
Documents Incorporated by Reference	Portions of the registrant’s definitive proxy statement relating to its 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended December 31, 2021 are incorporated herein by reference in Part III where indicated.
Entity Central Index Key	0001655210
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2021
Audit Information [Abstract]
Auditor Name	Deloitte & Touche LLP
Auditor Location	Los Angeles, California
Auditor Firm ID	34

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 733,294	$ 159,127
Accounts receivable, net	43,806	35,975
Inventory	241,870	121,717
Prepaid expenses and other current assets	33,078	15,407
Total current assets	1,052,048	332,226
Property, plant and equipment, net	226,489	115,299
Operating lease right-of-use assets	26,815	14,570
Prepaid lease costs, non-current	59,188	0
Other non-current assets, net	6,836	5,911
Investment in unconsolidated joint venture	8,023	0
Total assets	1,379,399	468,006
Current liabilities:
Accounts payable	69,040	53,071
Wages payable	155	2,843
Accrued bonus	128	57
Current portion of operating lease liabilities	4,458	3,095
Accrued expenses and other current liabilities	20,226	4,830
Short-term borrowings under revolving credit facility	0	25,000
Short-term finance lease liabilities	182	71
Total current liabilities	94,189	88,967
Long-term liabilities:
Convertible senior notes, net	1,129,674	0
Operating lease liabilities, net of current portion	22,599	11,793
Finance lease obligations and other long term liabilities	442	149
Total long-term liabilities	1,152,715	11,942
Commitments and Contingencies (Note 11)
Stockholders’ equity:
Preferred stock, par value $0.0001 per share—500,000 shares authorized, none issued and outstanding	0	0
Common stock, par value $0.0001 per share—500,000,000 shares authorized at December 31, 2021 and 2020; 63,400,899 and 62,820,351 shares issued and outstanding at December 31, 2021 and 2020, respectively	6	6
Additional paid-in capital	510,014	560,210
Accumulated deficit	(376,972)	(194,867)
Accumulated other comprehensive (loss) income	(553)	1,748
Total stockholders’ equity	132,495	367,097
Total liabilities and stockholders’ equity	$ 1,379,399	$ 468,006

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	500,000	500,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	500,000,000	500,000,000
Common stock, issued (in shares)	63,400,899	62,820,351
Common stock, outstanding (in shares)	63,400,899	62,820,351

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Net revenues	$ 464,700	$ 406,785	$ 297,897
Cost of goods sold	347,419	284,510	198,141
Gross profit	117,281	122,275	99,756
Research and development expenses	66,946	31,535	20,650
Selling, general and administrative expenses	209,474	133,655	74,726
Restructuring expenses	15,794	6,430	4,869
Total operating expenses	292,214	171,620	100,245
Income (loss) from operations	(174,933)	(49,345)	(489)
Other (expense) income, net:
Interest expense	(3,648)	(2,576)	(3,071)
Remeasurement of warrant liability	0	0	(12,503)
Other, net	(487)	(759)	3,629
Total other income (expense), net	(4,135)	(3,335)	(11,945)
Income (loss) before taxes	(179,068)	(52,680)	(12,434)
Income tax expense	60	72	9
Equity in losses of unconsolidated joint venture	2,977	0	0
Net income (loss)	$ (182,105)	$ (52,752)	$ (12,443)
Net loss per share available to common stockholders—basic (in dollars per share)	$ (2.88)	$ (0.85)	$ (0.29)
Net loss per share available to common stockholders—diluted (in dollars per share)	$ (2.88)	$ (0.85)	$ (0.29)
Weighted average common shares outstanding—basic (in shares)	63,172,368	62,290,445	42,274,777
Weighted average common shares outstanding—diluted (in shares)	63,172,368	62,290,445	42,274,777

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
Net loss	$ (182,105)	$ (52,752)	$ (12,443)
Other comprehensive (loss) income, net of tax:
Foreign currency translation (loss) gain, net of tax	(2,301)	1,748	0
Comprehensive loss, net of tax	$ (184,406)	$ (51,004)	$ (12,443)

Consolidated Statements of Conv

Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Comprehensive Income	IPO	IPOCommon Stock	IPOAdditional Paid-in Capital	Secondary Offering	Secondary OfferingCommon Stock	Secondary OfferingAdditional Paid-in Capital
Beginning balance (in shares) at Dec. 31, 2018	41,562,111
Beginning balance at Dec. 31, 2018	$ 199,540
Preferred Stock
Issuance of common stock upon conversion of convertible preferred stock (in shares)	(41,562,111)
Issuance of common stock upon conversion of convertible preferred stock	$ (199,540)
Ending balance (in shares) at Dec. 31, 2019	0
Ending balance at Dec. 31, 2019	$ 0
Beginning balance (in shares) at Dec. 31, 2018		6,951,350
Beginning balance at Dec. 31, 2018	(121,750)	$ 1	$ 7,921	$ (129,672)	$ 0
Common Stock
Net loss	(12,443)			(12,443)
Issuance of common stock, net (in shares)		41,562,111					11,068,750			250,000
Issuance of common stock, net	199,540	$ 4	199,536			$ 252,453	$ 1	$ 252,452	$ 37,394		$ 37,394
Issuance of common stock upon exercise of common stock warrants (in shares)		214,875
Reclassification of warrant liability to additional paid-in capital upon closing of the initial public offering	$ 14,421		14,421
Exercise of common stock options (in shares)	1,163,374	1,529,408
Exercise of common stock options	$ 2,669		2,669
Share-based compensation for equity-classified awards	11,806		11,806
Foreign currency translation (loss) gain, net of tax	0
Ending balance (in shares) at Dec. 31, 2019		61,576,494
Ending balance at Dec. 31, 2019	$ 384,090	$ 6	526,199	(142,115)	0
Ending balance (in shares) at Dec. 31, 2020	0
Ending balance at Dec. 31, 2020	$ 0
Common Stock
Net loss	(52,752)			(52,752)
Issuance of common stock under equity incentive plans, net (in shares)		1,243,857
Issuance of common stock under equity incentive plans, net	6,732		6,732
Issuance of common stock, net	0
Reclassification of warrant liability to additional paid-in capital upon closing of the initial public offering	0
Share-based compensation for equity-classified awards	27,279		27,279
Foreign currency translation (loss) gain, net of tax	1,748				1,748
Ending balance (in shares) at Dec. 31, 2020		62,820,351
Ending balance at Dec. 31, 2020	$ 367,097	$ 6	560,210	(194,867)	1,748
Ending balance (in shares) at Dec. 31, 2021	0
Ending balance at Dec. 31, 2021	$ 0
Common Stock
Net loss	(182,105)			(182,105)
Issuance of common stock under equity incentive plans, net (in shares)		580,548
Issuance of common stock under equity incentive plans, net	5,055		5,055
Issuance of common stock, net	0
Reclassification of warrant liability to additional paid-in capital upon closing of the initial public offering	$ 0
Exercise of common stock options (in shares)	485,016
Share-based compensation for equity-classified awards	$ 28,699		28,699
Purchase of capped calls related to convertible senior notes	(83,950)		(83,950)
Foreign currency translation (loss) gain, net of tax	(2,301)				(2,301)
Ending balance (in shares) at Dec. 31, 2021		63,400,899
Ending balance at Dec. 31, 2021	$ 132,495	$ 6	$ 510,014	$ (376,972)	$ (553)

Consolidated Statements of Co_2

Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
IPO
Stock offering costs	$ 4.9	$ 4.9
Secondary Offering
Stock offering costs	$ 1.1

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (182,105)	$ (52,752)	$ (12,443)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	21,663	13,299	8,106
Non-cash lease expense	3,418	2,341	0
Share-based compensation expense	27,698	27,279	12,807
Loss on sale of fixed assets	199	222	93
Amortization of debt issuance costs	3,322	256	181
Loss on extinguishment of debt	1,037	1,538	0
Equity in losses of unconsolidated joint venture	2,977	0	0
Change in preferred and common stock warrant liabilities	0	0	12,503
Net change in operating assets and liabilities:
Accounts receivable	(8,463)	4,516	(27,454)
Inventories	(122,666)	(38,863)	(51,339)
Prepaid expenses and other assets	(21,414)	(9,699)	(2,362)
Accounts payable	21,665	16,027	10,149
Accrued expenses and other current liabilities	13,961	(1,965)	2,743
Prepaid lease costs, non-current	(59,188)	0	0
Operating lease liabilities	(3,474)	(2,194)	0
Long-term liabilities	0	0	21
Net cash used in operating activities	(301,370)	(39,995)	(46,995)
Cash flows from investing activities:
Purchases of property, plant and equipment	(135,961)	(57,696)	(23,795)
Asset acquisition	0	(15,482)	0
Purchases of property, plant and equipment held for sale	0	(2,288)	(2,123)
Proceeds from note receivable on assets previously held for sale	0	599	299
Payments for investment in joint venture	(11,000)	0	0
Payment of security deposits	(518)	(33)	(545)
Net cash used in investing activities	(147,479)	(74,900)	(26,164)
Cash flows from financing activities:
Proceeds from issuance of common stock pursuant to the initial public offering, net of issuance costs	0	0	254,868
Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance costs	0	0	37,394
Proceeds from revolving credit facility	0	50,000	0
Proceeds from issuance of convertible senior notes	1,150,000	0	0
Purchase of capped calls related to convertible senior notes	(83,950)	0	0
Debt issuance costs	(23,605)	(1,224)	0
Debt extinguishment costs	0	(1,200)	0
Repayment of revolving credit facility	(25,000)	(25,000)	0
Repayment of revolving credit line	0	(6,000)	0
Repayment of term loan	0	(20,000)	0
Repayment of equipment loan	0	(5,000)	0
Principal payments under finance lease obligations	(177)	(70)	(55)
Proceeds from exercise of stock options	8,135	9,007	2,669
Payments of minimum withholding taxes on net share settlement of equity awards	(3,081)	(2,275)	0
Net cash provided by (used in) financing activities	1,022,322	(1,762)	294,876
Net increase (decrease) in cash and cash equivalents	573,473	(116,657)	221,717
Cash and cash equivalents at the beginning of the period	159,127	275,988	54,271
Effect of exchange rate changes on cash	694	(204)	0
Cash and cash equivalents at the end of the period	733,294	159,127	275,988
Cash paid (received) during the period for:
Interest	348	2,564	3,019
Taxes	(10)	18	9
Non-cash investing and financing activities:
Finance lease obligations for the purchase of property, plant and equipment	0	0	225
Non-cash additions to property, plant and equipment	5,239	10,719	1,418
Operating lease right-of-use assets obtained in exchange for lease liabilities	16,701	4,706	0
Non-cash addition to financing leases	580	0	0
Note receivable from sale of assets held for sale	0	4,558	0
Reclassification of other current liability to additional paid-in capital in connection with the share-settled obligation	2,535	0	0
Reclassification of warrant liability to additional paid-in capital in connection with the initial public offering	0	0	14,421
Conversion of convertible preferred stock to common stock upon initial public offering	$ 0	$ 0	$ 199,540

Introduction

Introduction	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Introduction	Introduction The Company Beyond Meat, Inc., a Delaware corporation (including its subsidiaries unless the context otherwise requires, the “Company”), is a leading plant-based meat company offering a portfolio of revolutionary plant-based meats. The Company builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating the Company’s plant-based meat products. The Company’s brand commitment, “Eat What You Love,” represents a strong belief that there is a better way to feed our future and that the positive choices we all make, no matter how small, can have a great impact on our personal health and the health of our planet. By shifting from animal-based meat to plant-based protein, we can positively impact four growing global issues: human health, climate change, constraints on natural resources and animal welfare. On September 7, 2018, the Company changed its name from Savage River, Inc. to Beyond Meat, Inc. On January 14, 2020, the Company registered its subsidiary, Beyond Meat EU B.V., in the Netherlands. On April 28, 2020, the Company registered its subsidiary, Beyond Meat (Jiaxing) Food Co., Ltd. (“BYND JX”), in the Zhejiang Province in China. On June 17, 2021, the Company incorporated its subsidiary, Beyond Meat Canada Inc., in Canada. On January 25, 2021, the Company entered into The PLANeT Partnership, LLC, a joint venture with PepsiCo, Inc., to develop, produce and market innovative snack and beverage products made from plant-based protein. The Company’s primary production facilities are located in Columbia, Missouri, and Devault, Pennsylvania, and its research and development and administrative offices are located in El Segundo, California. The Company owns a manufacturing facility in Enschede, the Netherlands, where it produces its woven protein and dry blend flavor systems for shipment to local co-manufacturers, including one of the Company’s distributors who built a co-manufacturing facility in the Netherlands used for production of the Company’s finished goods. In Jiaxing, China, the Company leases a manufacturing facility, where it produces its woven protein and houses end-to-end production. Renovations in the leased facility were substantially completed and trial production began in the first quarter of 2021. In the second quarter of 2021, several commercial trials of certain of the Company’s manufacturing processes were completed. Following the successful qualification of extrusion production capabilities in the third quarter of 2021 and the completion of International Food Safety System Certification (FSSC) 22000 and ISA Halal certification in the fourth quarter of 2021, the facility completed commercialization of end-to-end production at the end of 2021. In the fourth quarter of 2021, the Company also leased a facility in Shanghai, China, which will be used as a local research and development facility to support the Company’s local manufacturing operations. In addition to its own production facilities, the Company uses co-manufacturers in various locations in the United States, Canada and the Netherlands. In the third quarter of 2021, the Company completed the purchase of a facility in Columbia, Missouri. which is used primarily for warehousing and dry blending (ingredient handling). In the third quarter of 2021, the Company also assumed an operating lease for a building in Commerce, California to house its commercialization center. In addition to leasing its corporate headquarters and other general office space in El Segundo, California, the Company also leases a facility for its Manhattan Beach Project Innovation Center in El Segundo, California and an additional adjacent lab space. On January 14, 2021, the Company entered into a lease agreement to house its corporate headquarters, lab and innovation space in El Segundo, California. The Company sells to a variety of customers in the retail and foodservice channels throughout the United States and internationally primarily through distributors who purchase, store, sell, and deliver the Company’s products. In addition, the Company sells directly to customers in the retail and foodservice channels who handle their own distribution. As of December 31, 2021, approximately 90% of the Company’s long-lived assets were located in the United States. Initial Public Offering On May 6, 2019, the Company completed its initial public offering (“IPO”) of common stock in which it sold 11,068,750 shares. The shares began trading on the Nasdaq Global Select Market on May 2, 2019. The shares were sold at a public offering price of $25.00 per share for net proceeds of approximately $252.4 million, after deducting underwriting discounts and commissions of $19.4 million and issuance costs of approximately $4.9 million payable by the Company. Upon the closing of the IPO, all outstanding shares of the Company’s convertible preferred stock automatically converted into 41,562,111 shares of common stock on a one-for-one basis, and warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for a total of 160,767 shares of common stock. Secondary Public Offering On August 5, 2019, the Company completed a secondary public offering (“Secondary Offering”) of common stock in which it sold 250,000 shares and the selling stockholders sold 3,487,500 shares. The shares were sold at a public offering price of $160.00 per share for net proceeds to the Company of approximately $37.4 million, after deducting underwriting discounts and commissions of $1.5 million and issuance costs of approximately $1.1 million payable by the Company. Total Secondary Offering issuance costs paid in 2019 were approximately $2.2 million, of which approximately $1.1 million was capitalized to reflect the costs associated with the issuance of new shares and offset against proceeds from the Secondary Offering. The Company did not receive any proceeds from the sale of common stock by the selling stockholders. COVID-19 Pandemic On March 11, 2020, the World Health Organization declared COVID-19 a pandemic. The global spread and unprecedented impact of COVID-19 continues to create significant volatility, uncertainty and economic disruption. The Company’s operations and its financial results including net revenues, gross profit, gross margin and operating expenses were negatively impacted by COVID-19 in 2020 and 2021. The extent of COVID-19’s effect on the Company’s operational and financial performance will depend on future developments, including the duration, spread and intensity of the pandemic (including any resurgences), the impact of variants of the virus that causes COVID-19, the wide distribution and public acceptance of COVID-19 vaccines, labor needs at the Company as well as in the supply chain and at customers, compliance with government or employer COVID-19 vaccine mandates and the resulting impact on available labor, and the level of social and economic restrictions imposed in the United States and abroad in an effort to curb the spread of the virus, all of which are uncertain and difficult to predict considering the rapidly evolving landscape. As a result, it is not currently possible to ascertain the overall impact of COVID-19 on the Company’s business, results of operations, financial condition or liquidity. While the ultimate health and economic impact of COVID-19 continues to be highly uncertain, the Company expects that the adverse impact of COVID-19 on its business operations and results of operations, including its net revenues, gross profit, gross margin, earnings and cash flows, will continue into 2022. Future events and effects related to the COVID-19 pandemic cannot be determined with precision and actual results could significantly differ from estimates or forecasts. Emerging Growth Company Status Upon the completion of the Company’s IPO, the Company elected to be an Emerging Growth Company (“EGC”), as defined in the Jumpstart Our Business Startups Act (“JOBS Act”). Effective December 31, 2020, the Company lost its EGC status and is now categorized as a Large Accelerated Filer based upon the current market capitalization of the Company according to Rule 12b-2 of the Exchange Act. As a result, the Company must comply with all financial disclosure and governance requirements applicable to Large Accelerated Filers.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), and include the accounts of the Company and its subsidiaries. All inter-company balances and transactions have been eliminated. Fiscal Year The Company operates on a fiscal calendar year, and each interim quarter is comprised of one 5-week period and two 4-week periods, with each week ending on a Saturday. The Company’s fiscal year always begins on January 1 and ends on December 31. As a result, the Company’s first and fourth fiscal quarters may have more or fewer days included than a traditional 91-day fiscal quarter. Segment Information The Company has one operating segment and one reportable segment, as the Company’s chief operating decision maker, who is the Company’s Chief Executive Officer, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Management’s Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates made by the Company include trade promotion accruals; useful lives of property, plant and equipment; valuation of deferred tax assets; valuation of inventory; incremental borrowing rate used to determine operating lease right-of-use assets and operating lease liabilities; assessment of contract-based factors, asset-based factors, entity-based factors and market-based factors to determine the lease term impacting right-of-use assets and lease liabilities; the valuation of the fair value of stock options used to determine share-based compensation expense; the valuation of the fair value of common stock and preferred stock used in the remeasurement of warrants and liabilities; and loss contingency accruals in connection with claims, lawsuits and administrative proceedings. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates and such differences may be material to the financial statements. Comprehensive Loss Comprehensive loss includes unrealized gains (losses) on the Company’s foreign currency translation adjustments for the years ended December 31, 2021 and 2020. During the year ended December 31, 2019, the Company had no foreign operations, and as a result, comprehensive loss was equal to net loss for the year ended December 31, 2019. Income taxes on the unrealized losses are not material. Convertible Senior Notes On March 5, 2021, the Company issued $1.0 billion aggregate principal amount of its 0% Convertible Senior Notes due 2027 (the “Convertible Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act. On March 12, 2021, the initial purchasers of the Convertible Notes exercised their option to purchase an additional $150.0 million aggregate principal amount of the Company’s 0% Convertible Senior Notes due 2027 (the “Additional Notes”, and together with the Convertible Notes, the “Notes”), and such Additional Notes were issued on March 16, 2021. See Note 8 . The Company accounts for the Notes under Accounting Standards Update (“ASU”) No. 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity” (“ASU 2020-06”), which the Company early adopted in the first quarter of 2021 concurrent with the issuance of the Notes. The Company records the Notes in “Long-term liabilities” at face value net of issuance costs. If any of the conditions to the convertibility of the Notes is satisfied, or the Notes become due within one year, then the Company may be required under applicable accounting standards to reclassify the liability carrying value of the Notes as a current, rather than a long-term, liability. Capped Call Transactions Capped call transactions cover the aggregate number of shares of the Company’s common stock that will initially underlie the Notes, and generally reduce potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company may make in excess of the principal amount of the converted Notes, as the case may be, with such reduction and/or offset subject to a cap, based on the cap price of the capped call transactions. The Company determined that the freestanding capped call option contracts qualify as equity under the accounting guidance on indexation and equity classification, and recognized the contract by recording an entry to “Additional paid-in capital” (“APIC”) in stockholders’ equity in its consolidated balance sheet. The Company also determined that the capped call option contracts meet the definition of a derivative under Accounting Standards Codification (“ASC”) Topic 815, “Derivatives and Hedging” (“ASC 815”), but are not required to be accounted for as a derivative as they meet the scope exception outlined in ASC 815. Instead the capped call options are recorded in APIC and not remeasured. Issuance Costs Issuance costs related to the Notes offering were capitalized and offset against proceeds from the Notes. Issuance costs consist of legal and other costs related to the issuance of the Notes and are amortized to interest expense over the term of the Notes. Total issuance costs capitalized in the year ended December 31, 2021 were approximately $23.6 million, of which none remained unpaid as of December 31, 2021. There were no issuance costs related to the Notes in the year ended December 31, 2020. Foreign Currency The Company’s foreign entities use their local currency as the functional currency. For these entities, the Company translates net assets into U.S. dollars at period end exchange rates, while revenue and expense accounts are translated at average exchange rates prevailing during the periods being reported. Resulting currency translation adjustments are included in “Accumulated other comprehensive income” and foreign currency transaction gains and losses are included in “Other, net.” Transaction gains and losses on long-term intra-entity transactions are recorded as a component of “Other comprehensive (loss) income.” Transactions denominated in a currency other than the reporting entity’s functional currency may give rise to transaction gains and losses that impact the Company’s results of operations. Foreign currency translation (loss) income, net of tax, reported as cumulative translation adjustments through “Other comprehensive (loss) income” was $(2.3) million and $1.7 million, respectively, in the years ended December 31, 2021 and 2020. Realized and unrealized foreign currency transaction (losses) gains included in “Other, net” were $(0.2) million, $0.2 million and $0, respectively, in the years ended December 31, 2021, 2020 and 2019. Fair Value of Financial Instruments The fair value measurement accounting guidance creates a fair value hierarchy to prioritize the inputs used to measure fair value into three categories. A financial instrument’s level within the fair value hierarchy is based on the lowest level of input significant to the fair value measurement, where Level 1 is the highest and Level 3 is the lowest. The three levels are defined as follows: • Level 1 —Unadjusted quoted prices in active markets accessible by the reporting entity for identical assets or liabilities. Active markets are those in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. • Level 2 —Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active and model-derived valuations in which significant value drivers are observable. • Level 3 —Valuations derived from valuation techniques in which significant value drivers are unobservable. The Company’s financial instruments include cash equivalents, accounts receivable, accounts payable, and accrued expenses, for which the carrying amounts approximate fair value due to the short-term maturity of these financial instruments. The Company’s convertible notes are carried at face value less the unamortized debt issuance costs (see Note 8 ). The Company had no financial instruments measured at fair value on a recurring basis as of December 31, 2020, other than the liability classified share-settled obligation to one of the Company’s executive officers (see Note 10 Prior to the IPO, the stock warrant liability was measured at fair value using Level 3 inputs upon issuance and at each reporting date. Inputs used to determine the estimated fair value of the warrant liability as of the valuation date included expected term of the warrants, the risk-free interest rate, volatility, and the fair value of underlying shares. There were no transfers of financial assets or liabilities into or out of Level 1, Level 2 or Level 3 for 2021, 2020 or 2019. Cash and Cash Equivalents The Company maintains cash balances at two financial institutions in the United States. The cash balances may, at times, exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation or FDIC up to $250,000. The Company considers all highly liquid investments with original maturity dates of 90 days or less to be cash equivalents. Cash equivalents include approximately 90% in money market accounts and approximately 10% in demand deposits. Accounts Receivable The Company records accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any anticipated losses on the accounts receivable balances and recorded in allowance for doubtful accounts. Allowance for doubtful accounts is calculated based on the Company’s history of write-offs, level of past due accounts, and relationships with and economic status of the Company’s distributors or customers. The Company had $1.3 million and $0 allowance for doubtful accounts as of December 31, 2021 and 2020, respectively. Inventories and Cost of Goods Sold Inventories are recorded at lower of cost or net realizable value. The Company accounts for inventory using the weighted average cost method. In addition to product cost, inventory costs include expenditures such as direct labor and certain supply and overhead expenses including in-bound shipping and handling costs incurred in bringing the inventory to its existing condition and location. Inventories are comprised primarily of raw materials, direct labor and overhead costs. Weighted average cost method is used to absorb raw materials, direct labor, and overhead into inventory. The Company reviews inventory quantities on hand and records a provision for excess and obsolete inventory based primarily on historical demand and the age of the inventory, among other factors. Property, Plant and Equipment Property, plant and equipment are carried at cost less accumulated depreciation and are depreciated using the straight-line method over the following estimated useful lives: Land Not amortized Buildings 30 years Leasehold improvements Shorter of lease term or estimated useful life Furniture and fixtures 3 years Manufacturing equipment 5 to 10 years Research and development equipment 5 to 10 years Software and computer equipment 3 years Vehicles 5 years Leasehold improvements are depreciated on a straight-line basis over the lesser of the estimated useful life of the asset or the remaining lease term. When assets are sold or retired, the asset and related accumulated depreciation are removed from the respective account balances and any gain or loss on disposal is included in “Loss from operations.” Expenditures for repairs and maintenance are charged directly to expense when incurred. See Note 7 . Accounting for Acquisition The Company follows the guidance in ASC 805, “Business Combinations,” for determining whether an acquisition meets the definition of a business combination or asset acquisition. The acquired assets may include, but are not limited to land, building, building improvements, manufacturing equipment and assembled work force. For acquisitions that are accounted for as acquisitions of assets, the Company records the acquired tangible and intangible assets and assumed liabilities, if any, based on each asset’s and liability's relative fair value at the acquisition date to the total purchase price plus capitalized acquisition costs. The method for determining relative fair value varies depending on the type of asset. The Company has completed one acquisition to date. Impairment of Long-Lived Assets Long-lived assets, including property and equipment, are reviewed by management for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be fully recoverable. When events or circumstances indicate that impairment may be present, management evaluates the probability that future undiscounted net cash flows received will be less than the carrying amount of the asset. If projected future undiscounted cash flows are less than the carrying value of an asset, then such assets are written down to their fair values. The Company concluded that no long-lived assets were impaired during the fiscal years ended December 31, 2021, 2020 and 2019. Deferred Offering Costs Offering costs, consisting primarily of legal, accounting, printing and filing services, and other direct fees and costs related to the IPO, were capitalized and offset against proceeds from the IPO. Total IPO issuance costs were $4.9 million, of which $2.4 million was incurred and paid as of December 31, 2018 and an additional $2.5 million was incurred and paid in 2019. Total Secondary Offering costs paid in 2019 were approximately $2.2 million, of which approximately $1.1 million was capitalized to reflect the costs associated with the issuance of new shares and offset against proceeds from the Secondary Offering. The remainder of the Secondary Offering costs were associated with the expense of selling existing shares by the selling stockholders and were recorded in SG&A expenses in the statement of operations for 2019. There were no unpaid IPO issuance costs or Secondary Offering issuance costs in accounts payable or prepaid IPO issuance costs in prepaid expenses as of December 31, 2021 or 2020. Stock Warrant Liability The Company accounted for freestanding warrants outstanding to purchase shares of its common stock or, prior to its IPO, its convertible preferred stock or common stock, as a liability, as the underlying shares of convertible preferred stock and common stock were contingently redeemable and, therefore, could have obligated the Company to transfer assets at some point in the future. The warrants were recorded at fair value upon issuance and were subject to remeasurement at each balance sheet date. Any change in fair value has been recognized in the statements of operations in “Total other expense, net.” Prior to the IPO, the Company had outstanding warrants to purchase an aggregate of 60,002 shares of its common stock at an exercise price of $3.00 per share, 121,694 shares of its Series B convertible preferred stock at an exercise price of $1.07 per share and 39,073 shares of its Series E convertible preferred stock at an exercise price of $3.68 per share. On May 6, 2019, in connection with the IPO, the warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for a total of 160,767 shares of common stock at the same respective exercise price per share. Subsequent to the closing of the IPO, all outstanding warrants to purchase shares of common stock were cashless exercised. Income Taxes The Company is subject to federal and state income taxes. The Company uses the asset and liability method of accounting for income taxes as set forth in the authoritative guidance for accounting for income taxes. Under this method, the Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the respective carrying amounts and tax basis of assets and liabilities. A valuation allowance is established against the portion of deferred tax assets that the Company believes will not be realized on a more likely than not basis. With respect to uncertain tax positions, the Company recognizes in its financial statements those tax positions determined to be more likely than not of being sustained upon examination, based on the technical merits of the positions. The Company’s policy is to recognize, when applicable, interest and penalties on uncertain tax positions as part of income tax expense. See Note 12 . Leases The Company leases certain equipment used for research and development and operations under both finance and operating lease agreements. An asset and a corresponding liability for the finance lease obligations are established for the cost of a finance lease. Finance lease assets are included in “Property, plant and equipment, net” in the Company’s consolidated balance sheets. Operating leases include lease arrangements for the Company’s corporate offices, the Manhattan Beach Project Innovation Center, manufacturing and commercialization facilities, warehouses, vehicles and, to a lesser extent, equipment. Operating leases with a term greater than one year are recorded on the consolidated balance sheets as operating lease right-of-use assets and operating lease liabilities at the commencement date. Operating lease assets represent the right to use an underlying asset for the lease term, and operating lease liabilities represent the obligation to make lease payments arising from the lease. The Company records these balances initially at the present value of future minimum lease payments calculated using the Company’s incremental borrowing rate and expected lease term. The Company estimates the incremental borrowing rate for each operating lease based on prevailing market rates for collateralized debt in a similar economic environment with similar payment terms and maturity dates commensurate with the terms of the lease. Certain adjustments to the operating lease right-of-use assets may be required for items such as initial direct costs paid or incentives received. Certain leases contain variable payments, which are expensed as incurred and not included in the Company’s operating lease right-of-use assets and operating lease liabilities. These amounts primarily include payments for maintenance, utilities, taxes and insurance on the Company’s corporate, research and development, and manufacturing facilities and warehouse leases and are excluded from the present value of the Company’s lease obligations. Some leases also include early termination options, which can be exercised under specific conditions. The Company includes options to extend the lease term if the options are reasonably certain of being exercised. The Company currently considers its renewal options to be reasonably certain to be exercised. The Company does not have residual value guarantees or material restrictive covenants associated with its leases. Upon adoption of ASU 2016-02, the Company elected to combine lease and non-lease components on all new or modified leases into a single lease component, for all classes of assets other than the co-manufacturing class of assets, which the Company recognizes over the expected term on a straight-line expense basis. The Company elected to separate the lease and non-lease components on all new or modified operating leases for the co-manufacturing class of assets for the purpose of recording operating lease right-of-use assets and operating lease liabilities. Prior to fiscal 2020, the Company accounted for leases under ASC 840 and did not record operating leases on its consolidated balance sheets. See Note 4 . When the Company purchases property that it was previously leasing under an operating lease, the Company de-recognizes the right of use asset and liability and recognizes the difference between the purchase price and the carrying amount of the lease liability immediately before the purchase as an adjustment to the carrying value of the asset. The Company allocates the purchase price to the assets acquired based upon their relative values. Contingencies The Company is subject to a range of claims, lawsuits, and administrative proceedings that arise in the ordinary course of business. The Company accrues a liability (which amount includes litigation costs expected to be incurred) and charges operations for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated, in accordance with the recognition criteria of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 450, Contingencies . Estimating liabilities and costs associated with these matters require significant judgment based upon the professional knowledge and experience of management and its legal counsel. See Note 11 . Revenue Recognition In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which, along with subsequent ASUs, amended the existing accounting standards for revenue recognition (“Topic 606”). This guidance is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled to receive when products are transferred to customers. ASU 2014-09 was effective for the Company beginning January 1, 2019. The majority of the Company’s contracts with customers generally consist of a single performance obligation to transfer promised goods. Based on the Company’s evaluation and review of its contracts with customers, the timing and amount of revenue recognized based on ASU 2014-09 is consistent with the Company’s revenue recognition policy under previous guidance. The Company has therefore concluded that the adoption of ASU 2014-09 did not have a material impact on its financial position, results of operations, or cash flows. The Company’s revenues are generated through sales of its products to distributors or customers. Revenue is recognized at the point in which the performance obligation under the terms of a contract with the customer have been satisfied and control has transferred. The Company’s performance obligation is typically defined as the accepted purchase order, the direct-to-consumer order, or the contract with the customer which requires the Company to deliver the requested products at agreed upon prices at the time and location of the customer’s choice. The Company generally does not offer warranties or a right to return on the products it sells except in the instance of a product recall or other limited circumstances. Revenue is measured as the amount of consideration the Company expects to receive in exchange for fulfilling the performance obligation. Sales and other taxes the Company collects concurrent with the sale of products are excluded from revenue. The Company's normal payment terms vary by the type and location of its customers and the products offered. The time between invoicing and when payment is due is not significant. None of the Company's customer contracts as of December 31, 2021 contains a significant financing component. The Company routinely offers sales discounts and promotions through various programs to its customers and consumers. These programs include rebates, temporary on-shelf price reductions, off-invoice discounts, retailer advertisements, product coupons and other trade activities. Provision for discounts and incentives are recorded in the same period in which the related revenues are recognized. At the end of each accounting period, the Company recognizes a liability for estimated sales discounts that have been incurred but not paid which totaled $3.6 million as of December 31, 2021 and 2020. The offsetting charge is recorded as a reduction of revenues in the same period when the expense is incurred. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. The incremental cost to obtain contracts was not material. Presentation of Net Revenues by Channel Effective January 1, 2020, the Company began presenting net revenues by geography and distribution channel as follows: Distribution Channel Description U.S. Retail Net revenues from retail sales to the U.S. market (1) U.S. Foodservice Net revenues from restaurant and foodservice sales to the U.S. market International Retail Net revenues from retail sales to international markets, including Canada International Foodservice Net revenues from restaurant and foodservice sales to international markets, including Canada ____________ (1) Includes net revenues from direct-to-consumer sales. The following table presents the Company’s net revenues by channel: Year Ended December 31, 2021 2020 2019 (in thousands) U.S.: Retail $ 243,360 $ 264,111 $ 129,383 Foodservice 76,475 60,763 70,372 U.S. net revenues 319,835 324,874 199,755 International: Retail 81,483 36,472 15,426 Foodservice 63,382 45,439 82,716 International net revenues 144,865 81,911 98,142 Net revenues $ 464,700 $ 406,785 $ 297,897 Two distributors accounted for approximately 12% and 11% of the Company’s gross revenues in 2021; one customer accounted for approximately 13% of the Company’s gross revenues in 2020; and two distributors accounted for approximately 17% and 16%, respectively, of the Company’s gross revenues in 2019. No other distributor or customer accounted for more than 10% of the Company’s gross revenues in 2021, 2020 or 2019. Earnings (Loss) Per Share Earnings (loss) per share (“EPS”) represents net income available to common stockholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS represents net income available to common stockholders divided by the weighted-average number of common shares outstanding, inclusive of the dilutive impact of potential common shares outstanding during the period. Such potential common shares include options, unvested restricted stock, restricted stock units (“RSUs”), contracts classified as assets or liabilities that are required or assumed to be share-settled under the two-class method, warrants and convertible preferred stock. The Company calculates basic and diluted EPS available to common stockholders in conformity with the two-class method required for companies with participating securities. Pursuant to ASU 2020-06, the Company applies the more dilutive of the if-converted method and the two-class method to its Notes. The Company considers all series of convertible preferred stock issued and outstanding prior to the IPO to be participating securities. Under the two-class method, the net loss available to common stockholders was not allocated to the convertible preferred stock as the holders of convertible preferred stock issued and outstanding prior to the IPO did not have a contractual obligation to share in losses. Computation of EPS for the years ended December 31, 2021 and 2020 also excludes adjustments under the two-class method relating to a liability classified, share-settled obligation to an executive officer to deliver a variable number of shares based on a fixed monetary amount because the shares to be delivered are not participating securities as they do not have voting rights and are not entitled to participate in dividends until they are issued. Nonvested restricted stock awards (referred to as participating securities) are excluded from the dilutive impact of common equivalent shares outstanding in accordance with authoritative guidance under the two-class method. The nonvested restricted stockholders are entitled to participate in dividends declared on common stock as if the shares were fully vested and hence nonvested restricted stock shares are deemed to be participating securities. Under the two-class method, net income, but not net loss, available to nonvested restricted stockholders is excluded from net income available to common stockholders for purposes of calculating basic and diluted EPS. Net loss available to common stockholders is not allocated to unvested restricted stock as the holders of unvested restricted stock do not have a contractual obligation to share in losses. In periods when the Company records net loss, all potential common shares are excluded in the computation of EPS because their inclusion would be anti-dilutive. See Note 13 . Prepaid Expenses Prepaid expenses primarily include prepaid rent and insurance, which are expensed in the period to which they relate. Investment in Joint Venture The Company uses the equity method of accounting to record transactions associated with its joint venture when the Company shares in joint control of the investee. Investment in joint venture is not consolidated but is recorded in “Investment in unconsolidated joint venture” in the Company’s consolidated balance sheet. The Company recognizes its portion of the investee’s results in “Equity in losses of unconsolidated joint venture” in its consolidated statement of operations. Selling, General and Administrative (“SG&A”) Expenses SG&A expenses are primarily comprised of selling, marketing expenses and administrative expenses, share-based compensation, outbound shipping and handling costs, non-manufacturing rent expense, depreciation and amortization expense on non-manufacturing assets and other non-production operating expenses. Selling and marketing expenses include share-based compensation awards to brand ambassadors, advertising costs, costs associated with consumer promotions, product samples and sales aids incurred to acquire new customers, retain existing customers and build brand awareness. Administrative expenses include the expenses related to management, accounting, legal, IT, and other office functions. Advertising costs are expensed as incurred. Advertising costs in the years ended December 31, 2021, 2020 and 2019 were $12.1 million, $0.3 million and $0.3 million, respectively. Non-advertising related components of the Company’s total marketing expenditures primarily include costs associated with consumer promotions, product sampling and sales aids, which are also included in SG&A. Shipping and Handling Costs The Company does not bill its distributors or customers shipping and handling fees. The Company’s products are predominantly shipped to its distributors or customers as “FOB Destination,” with control of the products transferred to the customer at the destination. In-bound shipping and handling costs incurred in manufacturing a product are included in inventory and reflected in cost of goods sold when the sale of that product is recognized. Outbound shipping and handling costs, including shipping and handling costs related to direct-to-consumer sales, are considered as fulfillment costs and are recorded in SG&A expenses. Outbound shipping and handling costs included in SG&A expenses in 2021, 2020 and 2019 were $19.1 million, $11.9 million and $10.9 million, respectively. Research and Development Research and development costs, which includes enhancements to existing products and new product development, are expensed in the period incurred. Research and development expenses primarily consist of personnel and related expenses for the Company’s research and development staff, including salaries, benefits, bonuses, and share-based compensation, scale-up expenses, and depreciation and amortization expense on research and development assets. Future research and development expenses will include expenses associated with the Company’s new Commerce, California commercialization center. Research and development expenses in the years ended December 31, 2021, 2020 and 2019, were $66.9 million, $31.5 million and $20.7 million, respectively. Share-Based Compensation The Company me

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In May 2017, management approved a plan to terminate the Company’s exclusive supply agreement (the “Agreement”) with one of its co-manufacturers, due to non-performance under the Agreement and on May 23, 2017, the Company notified the co-manufacturer of its decision to terminate the Agreement. In accordance with the Company’s policy of reviewing long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable, the Company determined that as of May 23, 2017, the date the Company notified the co-manufacturer of its decision to terminate the Agreement, the assets held in possession of the co-manufacturer were no longer recoverable. In 2021, 2020 and 2019, the Company recorded $15.8 million, $6.4 million and $4.9 million, respectively, in restructuring expenses related to this dispute, which consisted primarily of legal and other expenses. See Note 11

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	LeasesLeases are classified as either finance leases or operating leases based on criteria in ASC 842. The Company has operating leases for its corporate offices, including its Manhattan Beach Project Innovation Center where the Company’s research and development facility is located, its manufacturing facilities, commercialization center, warehouses and vehicles, and to a lesser extent, certain equipment and finance leases for its equipment. Such leases generally have original lease terms between two include one or more options to renew. Some leases also include early termination options, which can be exercised under specific conditions. The Company includes options to extend the lease term if the options are reasonably certain of being exercised. The Company currently considers its renewal options to be reasonably certain to be exercised. The Company does not have residual value guarantees or material restrictive covenants associated with its leases. On January 1, 2020, the Company adopted ASU 2016-02 using the modified retrospective approach, which permits application of this new guidance at the beginning of the period of adoption, with comparative periods continuing to be reported under ASC 840. Operating lease assets represent the right to use an underlying asset for the lease term, and operating lease liabilities represent the obligation to make lease payments arising from the lease. The Company calculates the present value of its operating leases using an estimated incremental borrowing rate, which requires judgment. The Company estimates the incremental borrowing rate for each operating lease based on prevailing market rates for collateralized debt in a similar economic environment with similar payment terms and maturity dates commensurate with the terms of the lease. Certain leases contain variable payments, which are expensed as incurred and not included in the Company’s operating lease right-of-use assets and operating lease liabilities. These amounts primarily include payments for maintenance, utilities, taxes, and insurance on the Company’s corporate, research and development, and manufacturing facilities and warehouse leases and are excluded from the present value of the Company’s lease obligations. As part of this adoption, the Company elected to not record operating lease right-of-use assets or operating lease liabilities for leases with an initial term of 12 months or less. On January 14, 2021, the Company entered into a 12-year lease with two 5-year renewal options (“Campus Lease”) to house its corporate headquarters, lab and innovation space in El Segundo, California. The Company has not recognized an asset or a liability for the Campus Lease in its consolidated balance sheet as of December 31, 2021 because there was no lease commencement during the year ended December 31, 2021. Therefore, the Campus Lease is not included in the tables below. See Note 11 . In the third quarter of 2021, the Company completed the purchase of a property in Missouri, consisting of land, building, and associated tenant improvements, which it was leasing as an operating lease, for cash consideration of $10.4 million including transaction costs. The Company de-recognized the right of use asset and liability and recognized the difference between the purchase price and the carrying amount of the lease liability immediately before the purchase as an adjustment to the carrying value of the asset. The purchase price was allocated to the assets acquired based upon their relative values, which are included in “Property, plant and equipment, net” and “Other non-current assets,” on the Company’s consolidated balance sheets. In the third quarter of 2021, the Company also assumed an operating lease for a building comprising approximately 64,000 square feet in California to house its commercialization center. The lease expires in August 2033 and includes an option to extend the term for an additional 60 months. Lease costs for operating and finance leases were as follows: (in thousands) Statement of Operations Location Year Ended December 31, 2021 Year Ended December 31, 2020 Operating lease cost: Lease cost Cost of goods sold $ 2,583 $ 1,570 Lease cost Research and development expenses 652 621 Lease cost Selling, general and administrative expenses 961 569 Variable lease cost (1) Cost of goods sold 40 17 Operating lease cost $ 4,236 $ 2,777 Short-term lease cost Selling, general and administrative expenses $ 222 $ 311 Finance lease cost: Amortization of right-of use assets Cost of goods sold $ 177 75 Interest on lease liabilities Interest expense — $ 13 Finance lease cost $ 177 $ 88 Total lease cost (2) $ 4,635 $ 3,176 ____________ (1) Variable lease cost primarily consists of common area maintenance, such as cleaning and repairs. (2) Excludes Campus Lease. Supplemental balance sheet information related to leases are as follows: (in thousands) Balance Sheet Location December 31, 2021 December 31, 2020 Assets (1) Operating leases Operating lease right-of-use assets $ 26,815 $ 14,570 Finance leases, net Property, plant and equipment, net 615 212 Total lease assets $ 27,430 $ 14,782 Liabilities (1) Current: Operating lease liabilities Current portion of operating lease liabilities $ 4,458 $ 3,095 Finance lease liabilities Current portion of finance lease liabilities 182 71 Long-term: Operating lease liabilities Operating lease liabilities, net of current portion 22,599 11,793 Finance lease liabilities Finance lease obligations and other long-term liabilities 442 149 Total lease liabilities $ 27,681 $ 15,108 ____________ (1) Excludes Campus Lease. The following is a schedule by year of the maturities of lease liabilities with original terms in excess of one year, as of December 31, 2021: December 31, 2021 (in thousands) Operating Leases (1) Finance Leases 2022 $ 5,548 $ 194 2023 5,288 181 2024 3,543 147 2025 2,970 115 2026 2,831 9 Thereafter 12,984 — Total undiscounted future minimum lease payments 33,164 646 Less imputed interest (6,107) (22) Total discounted future minimum lease payments $ 27,057 $ 624 ____________ (1) Excludes Campus Lease. Weighted average remaining lease terms and weighted average discount rates were: December 31, 2021 Operating Leases (1) Finance Leases Weighted average remaining lease term (years) 8.4 3.6 Weighted average discount rate 4.4 % 2.3 % ____________ (1) Excludes Campus Lease.
Leases	LeasesLeases are classified as either finance leases or operating leases based on criteria in ASC 842. The Company has operating leases for its corporate offices, including its Manhattan Beach Project Innovation Center where the Company’s research and development facility is located, its manufacturing facilities, commercialization center, warehouses and vehicles, and to a lesser extent, certain equipment and finance leases for its equipment. Such leases generally have original lease terms between two include one or more options to renew. Some leases also include early termination options, which can be exercised under specific conditions. The Company includes options to extend the lease term if the options are reasonably certain of being exercised. The Company currently considers its renewal options to be reasonably certain to be exercised. The Company does not have residual value guarantees or material restrictive covenants associated with its leases. On January 1, 2020, the Company adopted ASU 2016-02 using the modified retrospective approach, which permits application of this new guidance at the beginning of the period of adoption, with comparative periods continuing to be reported under ASC 840. Operating lease assets represent the right to use an underlying asset for the lease term, and operating lease liabilities represent the obligation to make lease payments arising from the lease. The Company calculates the present value of its operating leases using an estimated incremental borrowing rate, which requires judgment. The Company estimates the incremental borrowing rate for each operating lease based on prevailing market rates for collateralized debt in a similar economic environment with similar payment terms and maturity dates commensurate with the terms of the lease. Certain leases contain variable payments, which are expensed as incurred and not included in the Company’s operating lease right-of-use assets and operating lease liabilities. These amounts primarily include payments for maintenance, utilities, taxes, and insurance on the Company’s corporate, research and development, and manufacturing facilities and warehouse leases and are excluded from the present value of the Company’s lease obligations. As part of this adoption, the Company elected to not record operating lease right-of-use assets or operating lease liabilities for leases with an initial term of 12 months or less. On January 14, 2021, the Company entered into a 12-year lease with two 5-year renewal options (“Campus Lease”) to house its corporate headquarters, lab and innovation space in El Segundo, California. The Company has not recognized an asset or a liability for the Campus Lease in its consolidated balance sheet as of December 31, 2021 because there was no lease commencement during the year ended December 31, 2021. Therefore, the Campus Lease is not included in the tables below. See Note 11 . In the third quarter of 2021, the Company completed the purchase of a property in Missouri, consisting of land, building, and associated tenant improvements, which it was leasing as an operating lease, for cash consideration of $10.4 million including transaction costs. The Company de-recognized the right of use asset and liability and recognized the difference between the purchase price and the carrying amount of the lease liability immediately before the purchase as an adjustment to the carrying value of the asset. The purchase price was allocated to the assets acquired based upon their relative values, which are included in “Property, plant and equipment, net” and “Other non-current assets,” on the Company’s consolidated balance sheets. In the third quarter of 2021, the Company also assumed an operating lease for a building comprising approximately 64,000 square feet in California to house its commercialization center. The lease expires in August 2033 and includes an option to extend the term for an additional 60 months. Lease costs for operating and finance leases were as follows: (in thousands) Statement of Operations Location Year Ended December 31, 2021 Year Ended December 31, 2020 Operating lease cost: Lease cost Cost of goods sold $ 2,583 $ 1,570 Lease cost Research and development expenses 652 621 Lease cost Selling, general and administrative expenses 961 569 Variable lease cost (1) Cost of goods sold 40 17 Operating lease cost $ 4,236 $ 2,777 Short-term lease cost Selling, general and administrative expenses $ 222 $ 311 Finance lease cost: Amortization of right-of use assets Cost of goods sold $ 177 75 Interest on lease liabilities Interest expense — $ 13 Finance lease cost $ 177 $ 88 Total lease cost (2) $ 4,635 $ 3,176 ____________ (1) Variable lease cost primarily consists of common area maintenance, such as cleaning and repairs. (2) Excludes Campus Lease. Supplemental balance sheet information related to leases are as follows: (in thousands) Balance Sheet Location December 31, 2021 December 31, 2020 Assets (1) Operating leases Operating lease right-of-use assets $ 26,815 $ 14,570 Finance leases, net Property, plant and equipment, net 615 212 Total lease assets $ 27,430 $ 14,782 Liabilities (1) Current: Operating lease liabilities Current portion of operating lease liabilities $ 4,458 $ 3,095 Finance lease liabilities Current portion of finance lease liabilities 182 71 Long-term: Operating lease liabilities Operating lease liabilities, net of current portion 22,599 11,793 Finance lease liabilities Finance lease obligations and other long-term liabilities 442 149 Total lease liabilities $ 27,681 $ 15,108 ____________ (1) Excludes Campus Lease. The following is a schedule by year of the maturities of lease liabilities with original terms in excess of one year, as of December 31, 2021: December 31, 2021 (in thousands) Operating Leases (1) Finance Leases 2022 $ 5,548 $ 194 2023 5,288 181 2024 3,543 147 2025 2,970 115 2026 2,831 9 Thereafter 12,984 — Total undiscounted future minimum lease payments 33,164 646 Less imputed interest (6,107) (22) Total discounted future minimum lease payments $ 27,057 $ 624 ____________ (1) Excludes Campus Lease. Weighted average remaining lease terms and weighted average discount rates were: December 31, 2021 Operating Leases (1) Finance Leases Weighted average remaining lease term (years) 8.4 3.6 Weighted average discount rate 4.4 % 2.3 % ____________ (1) Excludes Campus Lease.

Asset Acquisition

Asset Acquisition	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Asset Acquisition	Asset Acquisition On October 30, 2020, the Company acquired certain assets including land, building and improvements, manufacturing equipment, and assembled workforce from one of its former co-manufacturers (the “Seller”). The Company did not assume any liabilities of the Seller. The Company is using this manufacturing facility primarily for the production of its finished goods. Acquisition of these assets is expected to allow the Company to reduce manufacturing and packaging costs through vertical integration and provide opportunities for the Company to test new processes and scale new products more quickly. The total purchase consideration of $15.5 million was comprised of cash consideration of $14.5 million, subject to adjustment for customary prorations, transfer taxes, escrow holdbacks and other adjustments, and $1.0 million in acquisition-related expenses. As part of this transaction, the Company hired approximately 180 employees who were previously employed by the Seller. The Company accounted for this transaction as an asset acquisition and recorded the acquired tangible and intangible assets based on each asset’s relative fair value at the acquisition date to the total purchase price plus capitalized acquisition costs. Fair value of building and land were determined by a real estate appraisal prepared by an independent real estate appraiser. Fair value of assembled workforce was based on estimated replacement costs that utilize available market information and discount and/or capitalization rates as appropriate. The following table details the purchase price allocation of the acquired assets based on their relative fair values as of the acquisition date: (in thousands) Manufacturing equipment $ 1,273 Building 9,576 Land 2,774 Assembled workforce (1) 1,859 Total $ 15,482 _____________ (1) Assembled workforce is recorded in “Other non-current assets, net” in the consolidated balance sheet and will be amortized over an estimated useful life of approximately 2.0 years.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories Major classes of inventory were as follows: December 31, (in thousands) 2021 2020 Raw materials and packaging $ 129,974 $ 83,702 Work in process 50,227 12,887 Finished goods 61,669 25,128 Total $ 241,870 $ 121,717 The Company wrote off $12.5 million, $10.8 million and $6.4 million in excess and obsolete inventories and recognized that expense in cost of goods sold in its consolidated statements of operations for the years ended December 31, 2021, 2020 and 2019, respectively. The Company recorded $0.8 million and $0, respectively, in write down of inventory to lower of cost or net realizable value at December 31, 2021 and 2020.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, plant, and equipment are stated at cost and finance lease assets are included. A summary of property, plant, and equipment as of December 31, 2021 and 2020, is as follows: December 31, (in thousands) 2021 2020 Manufacturing equipment $ 115,412 $ 62,521 Research and development equipment 16,837 12,342 Leasehold improvements 20,250 9,277 Building 22,937 12,569 Finance leases 867 212 Software 1,297 402 Furniture and fixtures 868 614 Vehicles 584 377 Land 5,434 3,995 Assets not yet placed in service 95,455 46,148 Total property, plant and equipment $ 279,941 $ 148,457 Less: accumulated depreciation and amortization 53,452 33,158 Property, plant and equipment, net $ 226,489 $ 115,299 Depreciation and amortization expense in 2021, 2020 and 2019 was $21.7 million, $13.3 million and $8.1 million, respectively. Of the total depreciation and amortization expense in 2021, 2020 and 2019, $17.7 million, $10.1 million and $5.7 million, respectively, were recorded in cost of goods sold, $3.7 million, $3.1 million and $2.4 million, respectively, were recorded in research and development expenses, and $0.3 million, $0.1 million and $71,000, respectively, were recorded in SG&A expenses, in the Company’s consolidated statements of operations. The Company had no property, plant and equipment concluded to meet the criteria for assets held for sale as of December 31, 2021 and 2020. Amounts previously classified as assets held for sale were sold for amounts that approximated book value for which a note receivable of $3.8 million, net of payments received is included in “Other non-current assets, net” as of December 31, 2021.

Debt

Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt	Debt The following is a summary of debt balances as of December 31, 2021 and December 31, 2020: (in thousands) December 31, December 31, Convertible senior notes $ 1,150,000 $ — Revolving credit facility — 25,000 Debt issuance costs (20,326) — Total debt outstanding $ 1,129,674 $ 25,000 Less: current portion of long-term debt — 25,000 Long-term debt $ 1,129,674 $ — Convertible Senior Notes On March 5, 2021, the Company issued $1.0 billion aggregate principal amount of its 0% Convertible Senior Notes due 2027 (the “Convertible Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act. On March 12, 2021, the initial purchasers of the Convertible Notes exercised their option to purchase an additional $150.0 million aggregate principal amount of the Company’s 0% Convertible Senior Notes due 2027 (the “Additional Notes”, and together with the Convertible Notes, the “Notes”), and such Additional Notes were issued on March 16, 2021. The initial conversion price of the Notes is $206.00 per share of common stock, which represents a premium of approximately 47.5% over the closing price of the Company’s common stock on March 2, 2021. The Notes will mature on March 15, 2027, unless earlier repurchased, redeemed or converted. The Notes were issued pursuant to, and are governed by, an indenture, dated as of March 5, 2021 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee (the Trustee”). The Company used $84.0 million of the net proceeds from the sale of the Notes to fund the cost of entering into capped call transactions, described below. The proceeds from the issuance of the Notes were approximately $1.0 billion, net of capped call transaction costs of $84.0 million and debt issuance costs totaling $23.6 million. The Notes are senior, unsecured obligations and are (i) equal in right of payment with the Company’s senior, unsecured indebtedness; (ii) senior in right of payment to the Company’s indebtedness that is expressly subordinated to the Notes; (iii) effectively subordinated to the Company’s secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. The Notes do not bear regular interest, and the principal amount of the Notes do not accrete. However, special interest and additional interest may accrue on the Notes at a rate per annum not exceeding 0.50% (subject to certain exceptions) upon the occurrence of certain events relating to the failure to file certain SEC reports or to remove certain restrictive legends from the Notes. The initial conversion rate is 4.8544 shares of common stock per $1,000 principal amount of the Notes, which represents an initial conversion price of $206.00 per share of common stock. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events as described in the Indenture. The holder may convert the Notes during the five consecutive business days immediately after any ten consecutive trading day period, if the trading price per $1,000 principal amount of Notes, as determined following a request by a holder, for each trading day of the measurement period was less than ninety eight percent (98%) of the product of the last report sale price per share of common stock on such trading day and the conversion rate on such trading day. The holder can convert its Notes during any calendar quarter, commencing after the calendar quarter ending on June 30, 2021, provided the last reported sale price of the common stock for at least 20 trading days is greater than or equal to 130% of the conversion price, during the 30 consecutive trading days ending on the last trading day of a calendar quarter. Before December 15, 2026, noteholders have the right to convert their Notes upon the occurrence of certain events. From and after December 15, 2026, noteholders may convert their Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. The Company has the right to elect to settle conversions either in cash, shares or in a combination of cash and shares of its common stock. However, upon conversion of any Notes, the conversion value, which will be determined over an “Observation Period” (as defined in the Indenture) consisting of 20 trading days, will be paid in cash up to at least the principal amount of the Notes being converted. The Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after March 20, 2024 and on or before the 20th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. In addition, calling any Note for redemption will constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption. The Company must repay the note principal in cash, but may elect to settle the conversion value either in cash, shares or in a combination of cash and shares of its common stock. If certain corporate events that constitute a “Fundamental Change” (as defined in the Indenture) occur, then, subject to limited exceptions, noteholders may require the Company to repurchase their Notes at a cash repurchase price equal to the principal amount of the Notes to be repurchased, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the fundamental change repurchase date. The definition of Fundamental Change includes certain business combination transactions involving the Company and certain de-listing events with respect to the Company’s common stock. The Notes have customary provisions relating to the occurrence of “Events of Default” (as defined in the Indenture), which include the following: (i) certain payment defaults on the Notes (which, in the case of a default in the payment of special interest and additional interest on the Notes, are subject to a 30-day cure period); (ii) the Company’s failure to send certain notices under the Indenture within specified periods of time; (iii) the Company’s failure to comply with certain covenants in the Indenture relating to the Company’s ability to consolidate with or merge with or into, or sell, lease or otherwise transfer, in one transaction or a series of transactions, all or substantially all of the assets of the Company and its subsidiaries, taken as a whole, to another person; (iv) a default by the Company in its other obligations or agreements under the Indenture or the Notes if such default is not cured or waived within 60 days after notice is given in accordance with the Indenture; (v) certain defaults by the Company or any of its significant subsidiaries with respect to indebtedness for borrowed money of at least $100 million; and (vi) certain events of bankruptcy, insolvency and reorganization involving the Company or any of its significant subsidiaries. In the event of the Company’s liquidation, dissolution or winding up, holders of the Company’s common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of the Company’s debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock. Holders of the Company’s common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to the Company’s common stock. The rights, preferences and privileges of the holders of the Company’s common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that the Company may designate in the future. If an Event of Default involving bankruptcy, insolvency or reorganization events with respect to the Company (and not solely with respect to a significant subsidiary of the Company) occurs, then the principal amount of, and any accrued and unpaid special interest and additional interest on, all of the Notes then outstanding will immediately become due and payable without any further action or notice by any person. If any other Event of Default occurs and is continuing, then, the Trustee, by notice to the Company, or noteholders of at least 25% of the aggregate principal amount of Notes then outstanding, may declare the principal amount of, and any accrued and unpaid special interest and additional interest on, all of the Notes then outstanding to become due and payable immediately. However, notwithstanding the foregoing, the Company may elect, at its option, that the sole remedy for an Event of Default relating to certain failures by the Company to comply with certain reporting covenants in the Indenture consists exclusively of the right of the noteholders to receive special interest on the Notes for up to 365 days at a specified rate per annum not exceeding 0.50% on the principal amount of the Notes. The total amount of debt issuance costs of $23.6 million was recorded as a reduction to “Convertible senior notes, net” in the consolidated balance sheet and are being amortized as interest expense over the term of the Notes using the effective interest method. During the year ended December 31, 2021, the Company recognized $3.3 million in interest expense related to the amortization of the debt issuance costs related to the Notes. There was no such expense in the year ended December 31, 2020. The following is a summary of the Company’s Notes as of December 31, 2021: (in thousands) Principal Amount Unamortized Issuance Costs Net Carrying Amount Fair Value Amount Leveling 0% Convertible senior notes due on March 15, 2027 $ 1,150,000 $ 20,326 $ 1,129,674 $ 809,186 Level 2 The Notes are carried at face value less the unamortized debt issuance costs on the Company’s consolidated balance sheets. As of December 30, 2021, the estimated fair value of the Notes was approximately $809.2 million. The Notes are quoted on the Intercontinental Exchange and are classified as Level 2 financial instruments. The estimated fair value of the Notes was determined based on the actual bid price of the Notes on December 30, 2021, the last business day of the period. As of December 31, 2021, the remaining life of the Notes is approximately 5.2 years. Capped Call Transactions On March 2, 2021, in connection with the pricing of the offering of the Convertible Notes, the Company entered into capped call transactions (the “Base Capped Call Transactions”) with the option counterparties and used $73.0 million in net proceeds from the sale of the Convertible Notes to fund the cost of the Base Capped Call Transactions. On March 12, 2021, in connection with the Additional Notes, the Company entered into capped call transactions (the “Additional Capped Call Transactions”) with the option counterparties and used $11.0 million of the net proceeds from the sale of the Additional Notes to fund the cost of the Additional Capped Call Transactions. The Base Capped Call Transactions and the Additional Capped Call Transactions (collectively, the “Capped Call Transactions”) cover, subject to customary adjustments, the aggregate number of shares of the Company’s common stock that will initially underlie the Notes, and are expected generally to reduce potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company may make in excess of the principal amount of the converted Notes, as the case may be, with such reduction and/or offset subject to a cap, based on the cap price of the Capped Call Transactions. The cap price of the Capped Call Transactions is $279.32, which represents a premium of 100% over the last reported sale price of the Company’s common stock on March 2, 2021. The aggregate $84.0 million paid for the Capped Call Transactions was recorded as a reduction to APIC. Revolving Credit Facility On March 2, 2021, the Company terminated its secured revolving credit agreement, dated as of April 21, 2020 (the “Credit Agreement”), among the Company, as borrower, the lenders party thereto and JPMorgan Chase Bank, N.A., as the administrative agent, and in connection with such termination: (i) all borrowings outstanding under the Credit Agreement were repaid in full by the Company; and (ii) all liens and security interests under the Credit Agreement in favor of the lenders thereunder were released. The Company recorded debt issuance costs on the revolving credit facility in “Prepaid and other current assets, net,” in the accompanying consolidated balance sheet as of December 31, 2020. Debt issuance costs, net of amortization, totaled $0 and $1.1 million as of December 31, 2021 and December 31, 2020, respectively. Debt issuance costs are amortized as interest expense over the term of the loan. In the year ended December 31, 2021 debt issuance costs of $41,000, related to the Company’s prior revolving credit facility, were amortized to interest expense. In the years ended December 31, 2020 and 2019 debt issuance costs of $0.3 million and $0.2 million, respectively, related to the Company’s prior revolving credit facility and equipment loan were amortized to interest expense. In the years ended December 31, 2021, 2020 and 2019, the Company recorded $0.3 million, $2.1 million and $2.2 million, respectively, in interest expense related to its bank credit facilities. In the years ended December 31, 2021, 2020 and 2019, the Company recorded $0, $0.2 million and $0.6 million, respectively, in interest expense related to the Equipment Loan Facility. As of December 31, 2020, the Company had outstanding borrowings of $25.0 million and had no excess availability under the revolving credit facility. The interest rate on outstanding borrowings at December 31, 2020 was 3.5%. On February 25, 2021, the Company paid down the outstanding borrowings and had no borrowings outstanding under the revolving credit facility. Concurrent with the Company’s execution of the Campus Lease, as a security deposit, the Company delivered to the landlord a letter of credit under the revolving credit facility in the amount of $12.5 million. Upon termination of the revolving credit facility, the letter of credit continued in effect, unsecured. Equipment Loan Facility The Company had $5.0 million in borrowings outstanding as of December 31, 2019 under the equipment loan facility with Structural Capital Investments II, LP, as Lender, and Ocean II, PLC, LLC, as collateral agent and administrative agent (the “Equipment Loan Facility”). Concurrently with the effectiveness of the 2020 Credit Agreement, on April 21, 2020, the Company terminated the Equipment Loan Facility. The Company was in compliance with the financial covenants contained in the Equipment Loan Facility at the time of termination.

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit) and Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders’ Equity (Deficit) and Convertible Preferred Stock	Stockholders’ Equity (Deficit) and Convertible Preferred Stock Upon the closing of the IPO, all outstanding shares of the Company’s convertible preferred stock automatically converted into 41,562,111 shares of common stock on a one-for-one basis. On May 6, 2019, the Company filed a Restated Certificate of Incorporation authorizing the Company to issue 500,000,000 shares of common stock, $0.0001 par value per share, and $500,000 shares of undesignated preferred stock, $0.0001 par value per share, with rights and preferences determined by the Company’s Board of Directors at the time of issuance of such shares. On August 5, 2019, the Company completed its Secondary Offering of common stock, in which it sold 250,000 shares of common stock, $0.0001 par value. As of December 31, 2021, the Company had 63,400,899 shares of common stock issued and outstanding. As of December 31, 2020, the Company had 62,820,351 shares of common stock issued and outstanding. The Company has not declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based Compensation On April 11, 2011, the Company’s stockholders approved the 2011 Equity Incentive Plan (“2011 Plan”), and most recently amended the 2011 Plan on April 10, 2019. The 2011 Plan was amended, restated and re-named the 2018 Equity Incentive Plan (“2018 Plan”), which became effective as of April 30, 2019, the day prior to the effectiveness of the registration statement filed in connection with the IPO. The remaining shares available for issuance under the 2011 Plan were added to the shares reserved for issuance under the 2018 Plan. The 2018 Plan provides for the grant of stock options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, restricted stock units (“RSUs”), performance units, and performance shares to the Company’s employees, directors, and consultants. As of December 31, 2021, the maximum aggregate number of shares that may be issued under the 2018 Plan was 18,771,398 shares of the Company’s common stock. In addition, the number of shares reserved for issuance under the 2018 Plan will be increased automatically on the first day of each fiscal year beginning with the 2020 fiscal year, by a number equal to the least of: (i) 2,144,521 shares; (ii) 4.0% of the shares of common stock outstanding on the last day of the prior fiscal year; or (iii) such number of shares determined by the Company’s Board of Directors. As of January 1, 2022, the maximum aggregate number of shares that may be issued under the 2018 Plan increased to 20,915,919 shares. The 2018 Plan may be amended, suspended or terminated by the Company’s Board of Directors at any time, provided such action does not impair the existing rights of any participant, subject to stockholder approval of any amendment to the 2018 Plan as required by applicable law or listing requirements. Unless sooner terminated by the Company’s Board of Directors, the 2018 Plan will automatically terminate on November 14, 2028. The following table summarizes the shares available for grant under the 2018 Plan: Shares Available for Grant Balance - December 31, 2020 5,021,270 Authorized 2,144,521 Granted (1,038,429) Shares withheld to cover taxes 25,863 Forfeited 362,582 Balance - December 31, 2021 6,515,807 As of December 31, 2021 and 2020, there were 3,956,364 and 4,218,278 shares, respectively, issuable under stock options outstanding, 608,175 and 275,989 shares, respectively, issuable under unvested RSUs outstanding, and 7,730,884 and 7,127,079 shares, respectively, issued for stock option exercises, RSU settlement, and restricted stock grants. Stock Options Following are the assumptions used in the Black-Scholes valuation model for options granted during the periods shown below: Year Ended December 31, 2021 2020 2019 Risk-free interest rate 1.4% 1.3% 2.3% Average expected term (years) 7.0 7.0 6.1 Expected volatility 55.7% 55.0% 55.0% Dividend yield — — — • Risk-Free Interest Rate: The yield on actively traded non-inflation indexed US Treasury notes with the same maturity as the expected term of the underlying options was used as the average risk-free interest rate. • Expected Term: As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, the Company’s expected term is based on the simplified method, generally calculated as the mid-point between the vesting date and the end of the contractual term. • Expected Volatility: As the Company has only been a public entity since May 2, 2019, there is not a substantive share price history to calculate volatility and, as such, the Company has elected to use an approximation based on the volatility of other comparable public companies, which compete directly with the Company, over the expected term of the options. • Dividend Yield: The Company has not issued regular dividends on common shares in the past nor does the Company expect to issue dividends in the future. Forfeiture Rate: The Company estimates the forfeiture rate at the time of grant based on past awards canceled, the number of awards granted, and vesting terms and adjusted, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The cumulative effect on current and prior periods of a change in the estimated number of awards likely to vest is recognized in compensation cost in the period of the change. The 2018 Plan generally provides that the Board of Directors may set the vesting schedule applicable to grants approved under the 2018 Plan. The Company has not granted equity awards with performance-based vesting conditions. Option grants to new employees in 2021 and 2020 generally vest 25% of the total award on the first anniversary of the vesting commencement date, and thereafter ratably vesting monthly over the remaining three-year period, subject to continued employment through the vesting date. Option grants to continuing employees in 2021 and 2020 generally vest monthly over a 48-month period, subject to continued employment through the vesting date. Option grants to certain continuing employees in 2021 vest every six months over two years, subject to continued employment through the vesting date. An option grant to one executive officer in 2021 vested over three months from the vesting commencement date. Option grants in 2019 generally vest 25% of the total award on the first anniversary of the vesting commencement date, and thereafter ratably vesting monthly over the remaining three-year period, subject to continued employment through the vesting date. The stock option grant to one executive officer on August 1, 2019 vests monthly over a 48-month period. The stock option grant to another executive officer on October 31, 2019 began vesting on the second anniversary of the vesting commencement date and was scheduled to vest monthly thereafter over a 24-month period. The award was cancelled in its entirety when the executive officer resigned in the third quarter of 2021. The following table summarizes the Company’s stock option activity during the period from December 31, 2017 through December 31, 2021: Number Weighted Weighted Aggregate Intrinsic Value (in thousands) (1) Outstanding at December 31, 2018 5,120,293 $ 3.13 7.3 $ 81,371 Granted 1,571,925 $ 39.01 — $ — Exercised (1,429,756) $ 1.87 — $ 121,591 Cancelled/Forfeited (91,486) $ 9.33 — $ — Outstanding at December 31, 2019 5,170,976 $ 14.28 7.5 $ 329,879 Granted 268,193 $ 99.74 — $ — Exercised (1,163,374) $ 7.75 — $ 132,935 Cancelled/Forfeited (57,517) $ 37.14 — $ — Outstanding at December 31, 2020 4,218,278 $ 21.20 6.6 $ 443,595 Granted 475,520 $ 91.42 — $ — Exercised (485,016) $ 16.76 — $ 51,901 Cancelled/Forfeited (252,418) $ 70.41 — $ — Outstanding at December 31, 2021 3,956,364 $ 27.04 5.9 $ 180,302 Vested and exercisable at December 31, 2021 2,905,712 $ 14.20 5.0 $ 159,882 Vested and expected to vest at December 31, 2021 3,622,946 $ 22.34 5.6 $ 178,657 __________ (1) Aggregate intrinsic value is calculated as the difference between the value of common stock on the transaction date and the exercise price multiplied by the number of shares issuable under the stock option. Aggregate intrinsic value of shares outstanding at the beginning and end of the reporting period is calculated as the difference between the value of common stock on the beginning and end dates, respectively, and the exercise price multiplied by the number of shares outstanding. During the years ended December 31, 2021, 2020 and 2019, the Company recorded in aggregate $13.3 million, $13.1 million and $6.3 million, respectively, of share-based compensation expense related to options. The share-based compensation expense is included in cost of goods sold, research and development expenses and SG&A expenses in the Company’s consolidated statements of operations. As of December 31, 2021, there was $18.5 million in unrecognized compensation expense related to nonvested stock option awards which is expected to be recognized over a weighted average period of 1.5 years. Restricted Stock Units RSU grants to new employees in the year ended December 31, 2021 and 2020 vest 25% of the total award on the first anniversary of the vesting commencement date, and thereafter vest quarterly over the remaining three years of the award, subject to continued employment through the vesting date. RSU grants in the year ended December 31, 2021 include fully vested RSUs granted to an executive officer issued in settlement of the obligation discussed below under Share-Settled Obligation. An RSU grant to one executive officer in the year ended December 31, 2021 vested 100% over three months from the vesting commencement date. RSU grants to continuing employees in the year ended December 31, 2021 and 2020 generally vest quarterly over 16 quarters, subject to continued employment through the vesting date. In the year ended December 31, 2021, one RSU grant granted to continuing employees vests every 6 months over a two-year period, subject to continued employment through the vesting date. RSU grants to two executive officers in the year ended December 31, 2021 vest quarterly over four and eight quarters, respectively, subject to continued employment through the vesting date. Annual RSU grants to directors on the Company’s Board of Directors (the “Board”) vest monthly over a one-year period and RSU grants to new directors on the Board vest monthly over a three-year period. RSU grants to consultants and non-employee brand ambassadors in 2021 and 2020 have a variety of different vesting schedules. The following table summarizes the Company’s RSU activity from December 31, 2019 through December 31, 2021: Number of Units Weighted Unvested at December 31, 2019 149,004 $ 132.73 Granted 244,752 $ 109.61 Vested (99,970) $ 127.71 Cancelled/Forfeited (17,797) $ — Unvested at December 31, 2020 275,989 $ 114.99 Granted 562,909 $ 86 Vested (120,599) $ 123 Cancelled/Forfeited (110,124) $ — Unvested at December 31, 2021 608,175 $ 89 During the years ended December 31, 2021, 2020 and 2019, the Company recorded in aggregate $12.6 million, $9.8 million and $3.7 million, respectively, of share-based compensation expense related to RSUs. The share-based compensation expense is included in cost of goods sold, research and development expense and SG&A expenses in the Company’s consolidated statements of operations. As of December 31, 2021, there was $26.9 million in unrecognized compensation expense related to nonvested RSUs which is expected to be recognized over a weighted average period of 1.5 years. Share-Settled Obligation Share-based compensation expense in 2021 and 2020 includes $1.5 million and $3.0 million, respectively, for a liability classified, share-settled obligation to an executive officer related to a sign-on award pursuant to the terms of the executive officer’s offer letter with the Company. The share-based compensation expense related to this share-settled obligation is included in SG&A expenses in the Company’s consolidated statements of operations. The Company is obligated to deliver a variable number of shares based on a fixed monetary amount on the first annual anniversary of the executive officer’s commencement date and on each quarterly anniversary thereafter through the second annual anniversary. The liability classified award is considered unearned until the requirements for issuance of the shares are met and is included in “Accrued expenses and other current liabilities” in the Company’s consolidated balance sheet as of December 31, 2020 in the amount of $1.0 million. In 2021, two quarterly tranches related to this obligation were earned, and the Company delivered to the executive officer 20,872 fully vested RSUs with a settlement date fair value of $2.5 million. The executive officer separated from the Company effective August 27, 2021. As a result, the fourth quarterly tranche was unearned and cancelled. As of December 31, 2021, there was no accrued unrecognized compensation expense related to this share-settled obligation in “Accrued expenses and other current liabilities” in the Company’s consolidated balance sheet. Restricted Stock to Nonemployees In 2021 and 2020, the Company issued no restricted stock. In April 2019, the Company’s Board of Directors approved the issuance of 99,433 shares of restricted stock with a fair value of $20.02 per share and a purchase price of $0.01 per share to nonemployees serving as the Company’s brand ambassadors. The Company has the right to repurchase the unvested shares upon a voluntary or involuntary termination of a brand ambassador’s service; however, as shares vest monthly over 24 months, they are being released from the repurchase option and all such shares were released from the repurchase option by May 18, 2021. The following table summarizes the Company’s restricted stock activity: Number Weighted Weighted Unvested at December 31, 2019 88,988 1.2 19.49 Granted 0 — — Vested/Released (76,804) — 19.97 Cancelled/Forfeited — — — Unvested at December 31, 2020 12,184 0.3 20.02 Granted — — — Vested/Released (12,184) — 20.02 Cancelled/Forfeited — — — Unvested at December 31, 2021 — — — During 2021, 2020 and 2019, the Company recorded in aggregate $0.2 million, $1.4 million and $1.8 million, respectively, of share-based compensation expense related to restricted stock issued to nonemployee brand ambassadors, which is included in SG&A expenses in the Company’s consolidated statements of operations. As of December 31, 2021, there was $0 in unrecognized compensation expense related to nonvested restricted stock. Employee Stock Purchase Plan On November 15, 2018, the Company’s Board of Directors adopted its 2018 Employee Stock Purchase Plan (“2018 ESPP”), which was subsequently approved by the Company’s stockholders and became effective on April 30, 2019, the day immediately prior to the effectiveness of the registration statement filed in connection with the IPO. The 2018 ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code (the “Code”) for U.S. employees. In addition, the 2018 ESPP authorizes grants of purchase rights that do not comply with Section 423 of the Code under a separate non-423 component for non-U.S. employees and certain non-U.S. service providers. As of December 31, 2021, the Company has reserved 1,876,455 shares of common stock for issuance under the 2018 ESPP. In addition, the number of shares reserved for issuance under the 2018 ESPP will be increased automatically on the first day of each fiscal year for a period of up to ten years, starting with the 2020 fiscal year, by a number equal to the least of: (i) 536,130 shares; (ii) 1.0% of the shares of common stock outstanding on the last day of the prior fiscal year; or (iii) such lesser number of shares determined by the Company’s Board of Directors. As of January 1, 2022, the maximum aggregate number of shares that may be issued under the 2018 ESPP increased to 2,412,585 shares. The 2018 ESPP is expected to be implemented through a series of offerings under which participants are granted purchase rights to purchase shares of the Company’s common stock on specified dates during such offerings. The administrator has not yet approved an offering under the 2018 ESPP.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases See Note 4 , Leases . On January 14, 2021, the Company entered into a Lease (the “Campus Lease”) with HC Hornet Way, LLC, a Delaware limited liability company (the “Landlord”), to house the Company’s headquarters offices, lab and innovation space in El Segundo, California. The initial term of the Campus Lease is 12 years, commencing on the earlier of 210 days following substantial completion of the base building by the Landlord or the date the Company occupies any portion of the Premises (other than Phase I-A) for purposes of conducting business operations therein, subject to adjustment as provided in the Campus Lease. The Company has two renewal options, each for a period of five years. Under the terms of the Campus Lease, the Company will lease an aggregate of approximately 281,110 rentable square feet in a portion of a building located at 888 Douglas Street, El Segundo, California (the “Premises”), to be built out by the Landlord and delivered to the Company in three phases over a 26 month-period. Aggregate payments towards base rent for the Premises over the term of the lease will be approximately $159.3 million. In 2021, the Company paid $0.2 million in payments towards common area maintenance, parking, and insurance. No such payments were made in 2020 or 2019. Although the Company is involved in the design of the tenant improvements of the Premises, the Company does not have title or possession of the assets during construction. In addition, the Company does not have the ability to control the leased Premises until each phase of the tenant improvements is complete. As of December 31, 2021, the tenant improvements associated with Phase 1-A had not been completed, and the underlying asset had not been delivered to the Company. Accordingly, there was no lease commencement during the year ended December 31, 2021. Therefore, the Company has not recognized an asset or a liability for the Campus Lease in its consolidated balance sheet as of December 31, 2021. The Company contributed $59.2 million in payments to a construction escrow account in the year ended December 31, 2021. These payments are recorded in “Prepaid lease costs, non-current” in the Company’s consolidated balance sheet as of December 31, 2021, which will ultimately be recorded as a component of a right-of-use asset upon lease commencement. Concurrent with the Company’s execution of the Campus Lease, as a security deposit, the Company delivered to the Landlord a letter of credit in the amount of $12.5 million which amount will decrease to: (i) $6.3 million on the fifth (5th) anniversary of the Rent Commencement Date (as defined in the Campus Lease); (ii) $3.1 million on the eighth (8th) anniversary of the Rent Commencement Date; and (iii) $0 in the event the Company receives certain credit ratings; provided the Company is not then in default of its obligations under the Campus Lease. Upon termination of the revolving credit facility, the letter of credit continued in effect, unsecured. China Investment and Lease Agreement On September 22, 2020, the Company and BYND JX entered into an investment agreement with the Administrative Committee (the “JX Committee”) of the Jiaxing Economic & Technological Development Zone (the “JXEDZ”) pursuant to which, among other things, BYND JX has agreed to make certain investments in the JXEDZ in two phases of development, and the Company has agreed to guarantee certain repayment obligations of BYND JX under such agreement. In the year ended December 31, 2021, the Company received $1.1 million, in subsidies related to its investment in BYND JX from the Jiaxing Economic Development Zone Finance Bureau which is recorded in “Other, net” in the Company’s consolidated statement of operations. During Phase 1, the Company had agreed to invest $10.0 million in the JXEDZ through intercompany investment in BYND JX and BYND JX has agreed to lease a facility in the JXEDZ for a minimum of two years. In connection with such agreement, BYND JX entered into a factory leasing contract with an affiliate of the JX Committee, pursuant to which BYND JX has agreed to lease and renovate a facility in the JXEDZ and lease it for a minimum of two years. In the fourth quarter of 2021, the Company also entered into a leasing contract to house the Company’s research and development operations in the city of Shanghai for a period of eight years. As of December 31, 2021, the Company has invested $22.0 million and has advanced $20.0 million to its subsidiary, BYND JX. In the event that the Company and BYND JX determine, in their sole discretion, to proceed with the Phase 2 development in the JXEDZ, BYND JX has agreed in the first stage of Phase 2 to increase its registered capital by $30.0 million and to acquire the land use right to a state-owned land plot in the JXEDZ to conduct development and construction of a new production facility. Following the first stage of Phase 2, the Company and BYND JX may determine, in their sole discretion, to permit BYND JX to obtain a second state-owned land plot in the JXEDZ in order to construct an additional facility thereon. Investment in The PLANeT Partnership On January 25, 2021, the Company entered into The PLANeT Partnership, LLC (“TPP”), a joint venture with PepsiCo, Inc., to develop, produce and market innovative snack and beverage products made from plant-based protein. For the year ended December 31, 2021, the Company contributed its share of the investment in TPP, $11.0 million, and recognized its share of the net losses in TPP, in the amount of $3.0 million. No such amounts were recognized in 2020 or 2019. See Note 2 . Purchase Commitments As of December 31, 2021, the Company had committed to purchase pea protein inventory totaling $52.9 million in 2022, which excludes the pea protein supply agreement signed with Puris subsequent to the year end. See Note 14 . In addition, as of December 31, 2021, the Company had approximately $51.4 million in purchase order commitments for capital expenditures primarily to purchase machinery and equipment. Payments for these purchases will be due within 12 months from December 31, 2021. Litigation Don Lee Farms On May 25, 2017, Don Lee Farms, a division of Goodman Food Products, Inc., filed a complaint against the Company in the Superior Court of the State of California for the County of Los Angeles asserting claims for breach of contract, misappropriation of trade secrets, unfair competition under the California Business and Professions Code, money owed and due, declaratory relief and injunctive relief, each arising out of the Company’s decision to terminate an exclusive supply agreement between the Company and Don Lee Farms. The Company denied all of these claims and filed counterclaims on July 27, 2017, alleging breach of contract, unfair competition under the California Business and Professions Code and conversion. In October 2018, the former co-manufacturer filed an amended complaint that added one of the Company’s then current contract manufacturers as a defendant, principally for claims arising from the then current contract manufacturer’s alleged use of the former co-manufacturer’s alleged trade secrets, and for replacing the former co-manufacturer as one of the Company’s co-manufacturers. The then current contract manufacturer filed an answer denying all of Don Lee Farms’ claims and a cross-complaint against Beyond Meat asserting claims of total and partial equitable indemnity, contribution, and repayment. On March 11, 2019, Don Lee Farms filed a second amended complaint to add claims of fraud and negligent misrepresentation against the Company. On May 30, 2019, the judge denied the Company’s motion to dismiss the fraud and negligent misrepresentation claims, allowing the claims to proceed. On June 19, 2019, the Company filed an answer denying Don Lee Farms' claims. On January 24, 2020, a writ judge granted Don Lee Farms a right to attach in the amount of $628,689 on the grounds that Don Lee Farms had established a “probable validity” of its claim that Beyond Meat owes Don Lee Farms money for a small batch of unpaid invoices. This determination was not made by the trial judge. On January 27, 2020, Don Lee Farms filed a third amended complaint to add three individual defendants, all of whom are current or former employees of the Company, including Mark Nelson, the Company’s former Chief Financial Officer and Treasurer, to Don Lee Farms’ existing fraud claims alleging that those individuals were involved in the alleged fraudulent misrepresentations. On June 23, 2020, the judge denied Beyond Meat and the individual defendants’ motion to dismiss the fraud and negligent misrepresentation claims, allowing the claims to proceed. On July 6, 2020, the Company and the individual defendants filed an answer denying all of Don Lee Farms’ claims, including denying all allegations of fraud and negligent misrepresentation. On August 11, 2020, the Company filed an amended cross-complaint against Don Lee Farms, its parent Goodman Food Products, Inc. and its owners and employees, Donald, Daniel, and Brandon Goodman. Among other claims, the amended cross-complaint alleges that Don Lee Farms defrauded Beyond Meat, misappropriated its trade secrets, and infringed its trademarks. On January 28, 2021, Don Lee Farms filed a motion for summary adjudication on its breach of contract and money owed claims and on Beyond Meat’s breach of contract claims. On February 18, 2021, Don Lee Farms and Donald, Daniel and Brandon Goodman filed a motion for summary adjudication on Beyond Meat’s fraud, negligent misrepresentation, and conversion claims. On February 16, 2021, the Court entered an order consolidating this action with an action that Don Lee Farms filed against CLW Foods, LLC, a current Beyond Meat contract manufacturer. On February 22, 2021, CLW Foods, LLC requested a continuance of the trial date, which the Court granted. On March 19, 2021, Don Lee Farms requested the dismissal, without prejudice, of Don Lee Farms’ claims against the Company’s former contract manufacturer, ProPortion Foods, LLC and current contract manufacturer CLW Foods, LLC. On, March 23, 2021, ProPortion Foods, LLC requested that its claims against the Company be dismissed without prejudice. On March 26, 2021, the Court granted Don Lee Farms’ request to dismiss its claims against ProPortion Foods, LLC and CLW Foods, LLC; and granted ProPortion Foods, LLC request to dismiss its claims against the Company. On May 7, 2021, the Court ruled on Don Lee Farms’ motions for summary adjudication. The Court granted Don Lee Farms’ motion for summary adjudication on its breach of contract and money owed claims, and Beyond Meat’s negligent misrepresentation and conversion claims. The Court denied Don Lee Farms’ motion for summary adjudication on Beyond Meat’s breach of contract and fraud claims, allowing Beyond Meat’s claims to proceed to trial. On June 11, 2021, former Beyond Meat employees Mark Nelson and Tony Miller, and current employee, Jessica Quetsch (collectively, the “individual defendants”), filed a motion for summary judgment on Don Lee Farms’ fraud claim asserted against them. On June 11, 2021, the Company filed a motion for summary adjudication on Don Lee Farms’ fraud and negligent misrepresentation claims, misappropriation of trade secret claim, and unfair competition claim under the California Business and Professions Code. On August 27, 2021, the Court ruled on the individual defendants’ and the Company’s motions for summary adjudication. The Court denied the individual defendants’ motion for summary adjudication. The Court also denied the Company’s motion for summary adjudication on Don Lee Farms’ fraud and negligent misrepresentation claims. The Court granted the Company’s motion for summary adjudication on Don Lee Farms’ trade secret misappropriation and unfair competition claims. Don Lee Farms’ trade secret misappropriation and unfair competition claims will not proceed to trial. On January 27, 2022, Don Lee Farms filed a motion for summary adjudication on Beyond Meat’s trade secret misappropriation claim. The Court has not ruled on this motion. The hearing for this motion is scheduled for April 13, 2022. The previous trial date, September 27, 2021, was continued. Trial is currently set for May 16, 2022. Don Lee Farms is seeking from Beyond Meat and the individual defendants unspecified compensatory and punitive damages, declaratory and injunctive relief, and attorneys’ fees and costs. The Company is seeking from Don Lee Farms monetary damages, restitution of monies paid to Don Lee Farms, injunctive relief, including the prohibition of Don Lee Farms’ use or disclosure of Beyond Meat’s trade secrets and the prohibition of Don Lee Farms’ infringing use of Beyond Meat’s trademarks, and attorneys’ fees and costs. The Company believes it was justified in terminating the supply agreement with Don Lee Farms, that the Company is not liable for the fraud or negligent misrepresentation alleged in the third amended complaint, and that Don Lee Farms is liable for the conduct alleged in the Company’s amended cross-complaint. Conversely, as alleged in the Company’s amended cross-complaint, the Company believes Don Lee Farms misappropriated the Company’s trade secrets, defrauded the Company, and ultimately has infringed the Company’s trademarks. The Company is currently in the process of litigating this matter and intends to vigorously defend itself and its current and former employees against the claims and to prosecute the Company’s own claims. The Company cannot assure you that Don Lee Farms will not prevail in all or some of their claims against the Company or the individual defendants, or that the Company will prevail in some or all of its claims against Don Lee Farms. For example, if Don Lee Farms succeeds in the lawsuit, the Company could be required to pay damages, including but not limited to contract damages reasonably calculated at what the Company would have paid Don Lee Farms to produce the Company’s products through 2019, the end of the contract term. Based on the Company’s current knowledge, the Company has determined that the amount of any material loss or range of any losses that is reasonably possible to result from this lawsuit is not estimable. Securities Related Litigation On January 30, 2020, Larry Tran, a purported shareholder of Beyond Meat, filed a putative securities class action lawsuit in the United States District Court for the Central District of California against Beyond Meat and two of the Company’s executive officers, the Company’s President and CEO, Ethan Brown, and the Company’s former Chief Financial Officer and Treasurer, Mark Nelson. As noted here and in previous filings, the Tran securities class action was dismissed with prejudice on October 27, 2020, except for the class allegations of absent putative class members, which were dismissed without prejudice. On March 16, 2020, Eric Weiner, a purported shareholder of Beyond Meat, filed a shareholder derivative lawsuit in the United States District Court for the Central District of California, putatively on behalf of the Company, against two of the Company’s executive officers, the Company’s President and CEO, Ethan Brown, and the Company’s former Chief Financial Officer and Treasurer, Mark Nelson, and each of the Company’s directors, including one former director, who signed the Company’s initial public offering registration statement. The lawsuit asserts claims under Sections 10(b) and 21D of the Exchange Act, claims of breaches of fiduciary duty as directors and/or officers of Beyond Meat, and claims of unjust enrichment and waste of corporate assets, all relating to the Company’s ongoing litigation with Don Lee Farms, related actions taken by Beyond Meat and the named individuals during the period of May 2, 2019 to March 16, 2020, and the Tran securities case brought against the Company. On March 18, 2020, Kimberly Brink and Melvyn Klein, purported shareholders of Beyond Meat, filed a shareholder derivative lawsuit in the United States District Court for the Central District of California, putatively on behalf of the Company, against two of the Company’s executive officers, the Company’s President and CEO, Ethan Brown, and the Company’s former Chief Financial Officer and Treasurer, Mark Nelson, and each of the Company’s directors, including one former director, who signed the Company’s initial public offering registration statement. The lawsuit asserts claims under Sections 10(b) and 21D of the Exchange Act, claims of breaches of fiduciary duty as directors and/or officers of Beyond Meat, and claims of unjust enrichment and waste of corporate assets, all relating to the Company’s ongoing litigation with Don Lee Farms, related actions taken by Beyond Meat and the named individuals during the period of May 2, 2019 to March 18, 2020, and the Tran securities case brought against the Company. On May 27, 2020, Kevin Chew, a purported shareholder of Beyond Meat, filed a shareholder derivative lawsuit in the United States District Court of the District of Delaware (the “Chew Derivative Action”), putatively on behalf of the Company, against two of the Company’s executive officers, the Company’s President and CEO, Ethan Brown, and the Company’s former Chief Financial Officer and Treasurer, Mark Nelson, and each of the Company’s directors, including one former director, who signed the Company’s initial public offering registration statement. The lawsuit asserts claims under Sections 10(b) and 21D of the Exchange Act and claims of breaches of fiduciary duty, relating to the Company’s ongoing litigation with Don Lee Farms, related actions taken by Beyond Meat and the named individuals during the period of May 2, 2019 to May 27, 2020. On June 16, 2020, the Court entered an order staying all proceedings in the derivative action until (1) the Tran securities class action is dismissed, with prejudice, and all appeals related thereto have been exhausted; or (2) any motion to dismiss the Tran securities class action is denied in whole or in part. On June 17, 2020, the Court entered an order administratively closing the derivative case based on the stay order. On July 29, 2021, the Court entered a Joint Stipulation to Continue the Stay of the Action, staying the case until the resolution of the California Derivative Action. On April 1, 2020, the United States District Court for the Central District of California entered an order consolidating the Weiner action and the Brink/Klein action for all purposes and designated the consolidated case In re: Beyond Meat, Inc. Derivative Litigation (the “California Derivative Action”). On April 13, 2020, the Court entered an order appointing co-lead counsel for the California Derivative Action. On June 23, 2020, the Court entered an order approving a Joint Stipulation Regarding Stay of Actions. Under the terms of the stay approval order, all proceedings in the California Derivative Action are stayed until (1) the Tran securities class action is dismissed, with prejudice, and all appeals related thereto have been exhausted; or (2) any motion to dismiss the Tran securities class action is denied in whole or in part. As noted herein and in previous filings, the Tran securities class action was dismissed with prejudice on October 27, 2020, except for the class allegations of absent putative class members, which were dismissed without prejudice. On April 20, 2021, the parties filed a joint stipulation regarding briefing schedule, and the Court entered a schedule on April 21, 2021. On May 24, 2021, the plaintiffs in the California Derivative Action filed a First Amended Complaint (“FAC”). The FAC names the same defendants named in the originally-filed consolidated complaint and adds four additional defendants, including ProPortion Foods, LLC (“ProPortion”) and CLW Foods, LLC (“CLW”). The FAC asserts claims under Section 14(a) of the Exchange Act, claims of breach of fiduciary duty, unjust enrichment, waste of corporate assets, abuse of control and gross mismanagement against the individual defendants, and aiding and abetting claims against CLW and ProPortion. All of these claims relate to the Company’s dealings and ongoing litigation with Don Lee Farms, and related actions taken by Beyond Meat and the named individuals during the period of April 2016 to the present. On July 2, 2021, the Court entered a Joint Stipulation Regarding Extension of Briefing Schedule so that the parties could attempt to reach resolution of the lawsuit. The parties have reached a settlement of the California and Chew Derivative Actions. The proposed settlement, which is subject to Court approval, includes the Company enacting certain corporate governance reforms and paying plaintiffs’ attorney fees and costs in the amount of $515,000, which amount has been accrued as of December 31, 2021. No other payment is contemplated in the proposed settlement. On October 1, 2021, the parties filed a Joint Report Regarding Settlement in the Central District of California stating that the parties reached a tentative settlement and requesting that the Court (i) vacate the briefing schedule for Defendants’ motion to dismiss, and (ii) issue an order setting November 19, 2021 as the deadline on or before which Plaintiffs must move for preliminary approval of the settlement. On October 4, 2021, the Court entered such an order. The parties requested and received another extension to January 14, 2022 for Plaintiffs to file a motion for preliminary approval. The Stipulation of Settlement was signed on January 14, 2022, and Plaintiffs filed a motion for preliminary approval that same day. On February 8, 2022, the Court entered a Scheduling Notice and Order finding that Plaintiffs’ motion for preliminary approval is appropriate for submission on the papers without oral argument. The parties are waiting for the Court to rule on this motion. On June 17, 2020, James Janolek, a purported shareholder of Beyond Meat, filed a shareholder derivative lawsuit in the United States District Court of the District of Delaware, putatively on behalf of the Company, against two of the Company’s executive officers, the Company’s President and CEO, Ethan Brown, and the Company’s former Chief Financial Officer and Treasurer, Mark Nelson, and each of the Company’s directors, including one former director, who signed the Company’s initial public offering registration statement. The lawsuit asserts claims under Sections 14(a) and 20(a) of the Exchange Act, claims of breaches of fiduciary duty as directors and/or officers of Beyond Meat, and claims of unjust enrichment and waste of corporate assets, all relating to the Company’s ongoing litigation with Don Lee Farms, related actions taken by Beyond Meat and the named individuals during the period of May 2, 2019 to June 17, 2020. On July 10, 2020, the Court entered an order staying all proceedings in the derivative action until (1) the Tran securities class action is dismissed, with prejudice, and all appeals related thereto have been exhausted; or (2) any motion to dismiss the Tran securities class action is denied in whole or in part. On July 10, 2020, the Court entered an order administratively closing the derivative case based on the stay order. On November 9, 2020, Plaintiff filed a Notice of Voluntary Dismissal without prejudice and without costs or attorney fees to either party. The Company is involved in various other legal proceedings, claims, and litigation arising in the ordinary course of business. Based on the facts currently available, the Company does not believe that the disposition of such matters that are pending or asserted will have a material effect on its financial statements.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The provision for income taxes was as follows: (in thousands) Year Ended December 31, Current: 2021 2020 2019 Federal $ — $ — $ — State 60 72 9 $ 60 $ 72 $ 9 Deferred: Federal $ — $ — $ — State — — — $ — $ — $ — Provision for income tax $ 60 $ 72 $ 9 The Company has provided a 100% valuation allowance on its deferred tax assets. Provision for income taxes in 2021, 2020 and 2019 is primarily for taxes payable to the states. A reconciliation of income tax expense from continuing operations to the amount computed by applying the statutory federal income tax rate to the net loss from continuing operations is summarized as follows: Year Ended December 31, (in thousands) 2021 2020 2019 U.S. income tax at federal statutory rate $ (38,229) $ (11,063) $ (2,611) State income tax, net of federal benefits (4,991) (1,962) (2,550) Foreign rate differential (985) (54) — Stock warrant liability — — 2,626 Share-based compensation (4,932) (21,007) (21,236) Research and development credits (20) (10) (8) Change in tax rates (719) 2,989 73 Other 771 529 (98) Change in valuation allowance 49,165 30,650 23,813 Provision for income tax $ 60 $ 72 $ 9 Significant components of the Company's deferred tax assets and liabilities as of December 31, 2021, and 2020 are shown below. December 31, (in thousands) 2021 2020 Deferred Tax Assets: Net operating loss (NOL) $ 128,006 $ 78,464 Intangibles 1,308 1,495 Share-based compensation 4,584 3,295 Interest 388 311 Inventory reserve 2,139 2,262 Other 1,820 2,024 Total gross deferred tax assets 138,245 87,851 Deferred Tax liabilities: Property, plant and equipment 3,056 1,773 Other — — Total gross deferred tax liabilities 3,056 1,773 Valuation allowance 135,189 86,078 Net deferred tax assets (liabilities) $ — $ — As of December 31, 2021, and 2020, management assessed the realizability of deferred tax assets and evaluated the need for an amount of a valuation allowance for deferred tax assets on a jurisdictional basis. This evaluation utilizes the framework contained in ASC 740, “Income Taxes,” pursuant to which management analyzed all positive and negative evidence available at the balance sheet date to determine whether all or some portion of the deferred tax assets will not be realized. Under this guidance, a valuation allowance must be established for deferred tax assets when it is more likely than not (a probability level of more than 50%) that they will not be realized. In concluding on the evaluation, management placed significant emphasis on guidance in ASC 740, which states that “a cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome.” Based upon available evidence, it was concluded on a more-likely-than-not basis that certain deferred tax assets were not realizable as of December 31, 2021. Accordingly, a valuation allowance of $135.2 million has been recorded to offset these deferred tax assets. The change in valuation allowance for the year ended December 31, 2021 from 2020 was an increase of $49.1 million. As of December 31, 2021, the Company has accumulated federal, state and foreign net operating loss carryforwards of approximately $514.1 million, $201.7 million and $24.6 million, respectively, of which approximately $422.4 million of the federal net operating losses do not expire and the remaining federal, state and foreign tax loss carryforwards begin to expire in 2031, 2032 and 2025 respectively, unless previously utilized. As of December 31, 2020, the Company had accumulated federal, state and foreign net operating loss carryforwards of approximately $344.2 million, $92.5 million and $1.3 million, respectively. Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company's net operating loss (NOLs) and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed a section 382 analysis through December 31, 2019 and concluded ownership changes occurred in 2011, 2013 and 2015. However, these ownership changes are not expected to result in a material limitation on future use of the Company’s NOLs and credit carryforwards generated prior to these ownership changes pursuant. Changes may have occurred in 2020 and may occur in the future that could limit the Company's ability to utilize tax attributes. Any adjustment to the Company's tax attributes as a result of such ownership changes will result in a corresponding decrease to the valuation allowance recorded against the Company's deferred tax assets. The following table summarizes the activity related to the Company’s gross unrecognized tax benefits at the beginning and end of the years ended December 31, 2021 and 2020: Year Ended December 31, (in thousands) 2021 2020 Gross unrecognized tax benefits at the beginning of the year $ 5,399 $ 3,336 Increases related to current year positions 3,462 2,063 Increases/Decreases related to prior year positions — — Expiration of unrecognized tax benefits — — Gross unrecognized tax benefits at the end of the year $ 8,861 $ 5,399 As of December 31, 2021 and 2020, the Company had $8.0 million and $4.9 million, respectively, of unrecognized tax benefits from research and development tax credits, none of which, if recognized, would affect the Company’s effective tax rate. The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income tax expense. During the years ended December 31, 2021, 2020 and 2019, interest and penalties recognized were insignificant. The Company does not expect any significant increases or decreases to its unrecognized tax benefits within the next 12 months. The Company files U.S. federal, state and foreign income tax returns in jurisdictions with varying statute of limitations. The Company’s tax years from 2011 (inception) are subject to examination by the United States and state authorities due to the carry forward of unutilized tax attributes. With respect to the income of its foreign subsidiaries, the Company takes the position that the undistributed earnings of its foreign subsidiaries are permanently invested in that jurisdiction. As a result, no additional income taxes have been provided on the possible repatriation of these earnings to the parent company. The Company does not have any unremitted earnings as of December 31, 2021. The Tax Cuts and Jobs Act subjects a U.S. shareholder to tax on Global Intangible Low-taxes Income (“GILTI”) earned by certain foreign subsidiaries. Pursuant to the FASB Staff Q&A, Topic 740 No.5. Accounting for Global Intangible Low-taxed Income, the Company is allowed to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as period expense only. The Company has elected to account for GILTI in the year the tax is incurred. In response to the COVID-19 pandemic, the United States passed the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act in March 2020 and on March 11, 2021 the United States enacted the American Rescue Plan Act of 2021. These Acts include various income and payroll tax measures. The income tax and payroll tax measures did not materially impact the Company’s financial statements.

Net Loss Per Share Available to

Net Loss Per Share Available to Common Stockholders (“EPS”)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Loss Per Share Available to Common Stockholders (“EPS”)	Net Loss Per Share Available to Common Stockholders (“EPS”) The Company calculates basic and diluted net loss per share available to common stockholders in conformity with the two-class method required for companies with participating securities. Pursuant to ASU 2020-06, the Company applies the more dilutive of the if-converted method and the two-class method to its Notes. See Note 2 . Computation of EPS for the year ended December 31, 2021 and 2020 excludes the dilutive effect of 3,956,364 and 4,218,278 shares issuable under stock options, respectively, and 608,175 and 275,989 RSUs, respectively, because the Company incurred a net loss and their inclusion would have been antidilutive. Computation of EPS for the year ended December 31, 2020 also excludes adjustments under the two-class method relating to a liability classified, share-settled obligation to an executive officer to deliver a variable number of shares based on a fixed monetary amount because the shares to be delivered are not participating securities as they do not have voting rights and are not entitled to participate in dividends until they are issued. The share-settled obligation that was scheduled to vest in the third quarter of 2021 was cancelled because the executive officer separated from the Company before the vest date and the award was not earned (see Note 9 ). Computation of net loss per share available to common stockholders for the year ended December 31, 2021 also excludes the dilutive effect of the Notes because the Company recorded a net loss and their inclusion would be anti-dilutive. Computation of EPS for the year ended December 31, 2019 excludes the dilutive effect of 5,170,976 shares issuable under stock options because the Company incurred a net loss and their inclusion would have been antidilutive. (in thousands, except share and per share amounts) Year Ended December 31, 2021 2020 2019 Numerator: Net loss available to common stockholders $ (182,105) $ (52,752) $ (12,443) Undistributed net income available to unvested restricted stockholders — — — Net loss available to common stockholders—basic $ (182,105) $ (52,752) $ (12,443) Denominator: Weighted average common shares outstanding—basic 63,172,368 62,290,445 42,274,777 Dilutive effect of shares issuable under stock options — — — Dilutive effect of RSUs — — — Dilutive effect of share-settled obligation — — — Dilutive effect of Notes, if converted (1) — — — Weighted average common shares outstanding—diluted 63,172,368 62,290,445 42,274,777 Net loss per share available to common stockholders—basic $ (2.88) $ (0.85) $ (0.29) ______________ (1) As the Company recorded a net loss in the year ended December 31, 2021, inclusion of shares from the conversion premium or spread would be anti-dilutive. The Company had no Notes outstanding during the years ended December 31, 2020 and 2019. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share available to common stockholders for the periods presented because the impact of including them would have been antidilutive: Year Ended December 31, 2021 2020 2019 Options to purchase common stock 3,956,364 4,218,278 5,170,976 Restricted stock units 608,175 275,989 149,004 Total 4,564,539 4,494,267 5,319,980

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Event	Subsequent EventSubsequent to the year ended December 31, 2021, on February 8, 2022, the Company amended its supply agreement with PURIS Proteins, LLC., under which it may purchase domestically sourced pea protein and extended it through December 31, 2022.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of PresentationThe consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), and include the accounts of the Company and its subsidiaries. All inter-company balances and transactions have been eliminated.
Fiscal Year	Fiscal Year The Company operates on a fiscal calendar year, and each interim quarter is comprised of one 5-week period and two 4-week periods, with each week ending on a Saturday. The Company’s fiscal year always begins on January 1 and ends on December 31. As a result, the Company’s first and fourth fiscal quarters may have more or fewer days included than a traditional 91-day fiscal quarter.
Segment Information	Segment Information The Company has one operating segment and one reportable segment, as the Company’s chief operating decision maker, who is the Company’s Chief Executive Officer, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.
Management’s Use of Estimates	Management’s Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates made by the Company include trade promotion accruals; useful lives of property, plant and equipment; valuation of deferred tax assets; valuation of inventory; incremental borrowing rate used to determine operating lease right-of-use assets and operating lease liabilities; assessment of contract-based factors, asset-based factors, entity-based factors and market-based factors to determine the lease term impacting right-of-use assets and lease liabilities; the valuation of the fair value of stock options used to determine share-based compensation expense; the valuation of the fair value of common stock and preferred stock used in the remeasurement of warrants and liabilities; and loss contingency accruals in connection with claims, lawsuits and administrative proceedings. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates and such differences may be material to the financial statements.
Comprehensive Loss	Comprehensive Loss Comprehensive loss includes unrealized gains (losses) on the Company’s foreign currency translation adjustments for the years ended December 31, 2021 and 2020. During the year ended December 31, 2019, the Company had no foreign operations, and as a result, comprehensive loss was equal to net loss for the year ended December 31, 2019. Income taxes on the unrealized losses are not material.
Convertible Senior Notes and Issuance Costs	Convertible Senior Notes On March 5, 2021, the Company issued $1.0 billion aggregate principal amount of its 0% Convertible Senior Notes due 2027 (the “Convertible Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act. On March 12, 2021, the initial purchasers of the Convertible Notes exercised their option to purchase an additional $150.0 million aggregate principal amount of the Company’s 0% Convertible Senior Notes due 2027 (the “Additional Notes”, and together with the Convertible Notes, the “Notes”), and such Additional Notes were issued on March 16, 2021. See Note 8 . The Company accounts for the Notes under Accounting Standards Update (“ASU”) No. 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity” (“ASU 2020-06”), which the Company early adopted in the first quarter of 2021 concurrent with the issuance of the Notes. The Company records the Notes in “Long-term liabilities” at face value net of issuance costs. If any of the conditions to the convertibility of the Notes is satisfied, or the Notes become due within one year, then the Company may be required under applicable accounting standards to reclassify the liability carrying value of the Notes as a current, rather than a long-term, liability.
Capped Call Transactions	Capped Call Transactions Capped call transactions cover the aggregate number of shares of the Company’s common stock that will initially underlie the Notes, and generally reduce potential dilution to the Company’s common stock upon any conversion of Notes and/or offset any cash payments the Company may make in excess of the principal amount of the converted Notes, as the case may be, with such reduction and/or offset subject to a cap, based on the cap price of the capped call transactions. The Company determined that the freestanding capped call option contracts qualify as equity under the accounting guidance on indexation and equity classification, and recognized the contract by recording an entry to “Additional paid-in capital” (“APIC”) in stockholders’ equity in its consolidated balance sheet. The Company also determined that the capped call option contracts meet the definition of a derivative under Accounting Standards Codification (“ASC”) Topic 815, “Derivatives and Hedging” (“ASC 815”), but are not required to be accounted for as a derivative as they meet the scope exception outlined in ASC 815. Instead the capped call options are recorded in APIC and not remeasured.
Foreign Currency	Foreign CurrencyThe Company’s foreign entities use their local currency as the functional currency. For these entities, the Company translates net assets into U.S. dollars at period end exchange rates, while revenue and expense accounts are translated at average exchange rates prevailing during the periods being reported. Resulting currency translation adjustments are included in “Accumulated other comprehensive income” and foreign currency transaction gains and losses are included in “Other, net.” Transaction gains and losses on long-term intra-entity transactions are recorded as a component of “Other comprehensive (loss) income.” Transactions denominated in a currency other than the reporting entity’s functional currency may give rise to transaction gains and losses that impact the Company’s results of operations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value measurement accounting guidance creates a fair value hierarchy to prioritize the inputs used to measure fair value into three categories. A financial instrument’s level within the fair value hierarchy is based on the lowest level of input significant to the fair value measurement, where Level 1 is the highest and Level 3 is the lowest. The three levels are defined as follows: • Level 1 —Unadjusted quoted prices in active markets accessible by the reporting entity for identical assets or liabilities. Active markets are those in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. • Level 2 —Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active and model-derived valuations in which significant value drivers are observable. • Level 3 —Valuations derived from valuation techniques in which significant value drivers are unobservable. The Company’s financial instruments include cash equivalents, accounts receivable, accounts payable, and accrued expenses, for which the carrying amounts approximate fair value due to the short-term maturity of these financial instruments. The Company’s convertible notes are carried at face value less the unamortized debt issuance costs (see Note 8 ). The Company had no financial instruments measured at fair value on a recurring basis as of December 31, 2020, other than the liability classified share-settled obligation to one of the Company’s executive officers (see Note 10
Cash and Cash Equivalents	Cash and Cash Equivalents The Company maintains cash balances at two financial institutions in the United States. The cash balances may, at times, exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation or FDIC up to $250,000. The Company considers all highly liquid investments with original maturity dates of 90 days or less to be cash equivalents. Cash equivalents include approximately 90% in money market accounts and approximately 10% in demand deposits.
Accounts Receivable	Accounts Receivable The Company records accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any anticipated losses on the accounts receivable balances and recorded in allowance for doubtful accounts. Allowance for doubtful accounts is calculated based
Inventories and Cost of Goods Sold	Inventories and Cost of Goods SoldInventories are recorded at lower of cost or net realizable value. The Company accounts for inventory using the weighted average cost method. In addition to product cost, inventory costs include expenditures such as direct labor and certain supply and overhead expenses including in-bound shipping and handling costs incurred in bringing the inventory to its existing condition and location. Inventories are comprised primarily of raw materials, direct labor and overhead costs. Weighted average cost method is used to absorb raw materials, direct labor, and overhead into inventory. The Company reviews inventory quantities on hand and records a provision for excess and obsolete inventory based primarily on historical demand and the age of the inventory, among other factors.
Inventories and Cost of Goods Sold	Inventories and Cost of Goods SoldInventories are recorded at lower of cost or net realizable value. The Company accounts for inventory using the weighted average cost method. In addition to product cost, inventory costs include expenditures such as direct labor and certain supply and overhead expenses including in-bound shipping and handling costs incurred in bringing the inventory to its existing condition and location. Inventories are comprised primarily of raw materials, direct labor and overhead costs. Weighted average cost method is used to absorb raw materials, direct labor, and overhead into inventory. The Company reviews inventory quantities on hand and records a provision for excess and obsolete inventory based primarily on historical demand and the age of the inventory, among other factors.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are carried at cost less accumulated depreciation and are depreciated using the straight-line method over the following estimated useful lives: Land Not amortized Buildings 30 years Leasehold improvements Shorter of lease term or estimated useful life Furniture and fixtures 3 years Manufacturing equipment 5 to 10 years Research and development equipment 5 to 10 years Software and computer equipment 3 years Vehicles 5 years
Accounting for Acquisition	Accounting for Acquisition The Company follows the guidance in ASC 805, “Business Combinations,” for determining whether an acquisition meets the definition of a business combination or asset acquisition. The acquired assets may include, but are not limited to land, building, building improvements, manufacturing equipment and assembled work force.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets, including property and equipment, are reviewed by management for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be fully recoverable. When events or circumstances indicate that impairment may be present, management evaluates the probability that future undiscounted net cash flows received will be less than the carrying amount of the asset. If projected future undiscounted cash flows are less than the carrying value of an asset, then such assets are written down to their fair values.
Deferred Offering Costs	Deferred Offering CostsOffering costs, consisting primarily of legal, accounting, printing and filing services, and other direct fees and costs related to the IPO, were capitalized and offset against proceeds from the IPO.
Stock Warrant Liability	Stock Warrant Liability The Company accounted for freestanding warrants outstanding to purchase shares of its common stock or, prior to its IPO, its convertible preferred stock or common stock, as a liability, as the underlying shares of convertible preferred stock and common stock were contingently redeemable and, therefore, could have obligated the Company to transfer assets at some point in the future. The warrants were recorded at fair value upon issuance and were subject to remeasurement at each balance sheet date. Any change in fair value has been recognized in the statements of operations in “Total other expense, net.”
Income Taxes	Income Taxes The Company is subject to federal and state income taxes. The Company uses the asset and liability method of accounting for income taxes as set forth in the authoritative guidance for accounting for income taxes. Under this method, the Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the respective carrying amounts and tax basis of assets and liabilities. A valuation allowance is established against the portion of deferred tax assets that the Company believes will not be realized on a more likely than not basis.
Leases	Leases The Company leases certain equipment used for research and development and operations under both finance and operating lease agreements. An asset and a corresponding liability for the finance lease obligations are established for the cost of a finance lease. Finance lease assets are included in “Property, plant and equipment, net” in the Company’s consolidated balance sheets. Operating leases include lease arrangements for the Company’s corporate offices, the Manhattan Beach Project Innovation Center, manufacturing and commercialization facilities, warehouses, vehicles and, to a lesser extent, equipment. Operating leases with a term greater than one year are recorded on the consolidated balance sheets as operating lease right-of-use assets and operating lease liabilities at the commencement date. Operating lease assets represent the right to use an underlying asset for the lease term, and operating lease liabilities represent the obligation to make lease payments arising from the lease. The Company records these balances initially at the present value of future minimum lease payments calculated using the Company’s incremental borrowing rate and expected lease term. The Company estimates the incremental borrowing rate for each operating lease based on prevailing market rates for collateralized debt in a similar economic environment with similar payment terms and maturity dates commensurate with the terms of the lease. Certain adjustments to the operating lease right-of-use assets may be required for items such as initial direct costs paid or incentives received. Certain leases contain variable payments, which are expensed as incurred and not included in the Company’s operating lease right-of-use assets and operating lease liabilities. These amounts primarily include payments for maintenance, utilities, taxes and insurance on the Company’s corporate, research and development, and manufacturing facilities and warehouse leases and are excluded from the present value of the Company’s lease obligations. Some leases also include early termination options, which can be exercised under specific conditions. The Company includes options to extend the lease term if the options are reasonably certain of being exercised. The Company currently considers its renewal options to be reasonably certain to be exercised. The Company does not have residual value guarantees or material restrictive covenants associated with its leases. Upon adoption of ASU 2016-02, the Company elected to combine lease and non-lease components on all new or modified leases into a single lease component, for all classes of assets other than the co-manufacturing class of assets, which the Company recognizes over the expected term on a straight-line expense basis. The Company elected to separate the lease and non-lease components on all new or modified operating leases for the co-manufacturing class of assets for the purpose of recording operating lease right-of-use assets and operating lease liabilities. Prior to fiscal 2020, the Company accounted for leases under ASC 840 and did not record operating leases on its consolidated balance sheets. See Note 4 . When the Company purchases property that it was previously leasing under an operating lease, the Company de-recognizes the right of use asset and liability and recognizes the difference between the purchase price and the carrying amount of the lease liability immediately before the purchase as an adjustment to the carrying value of the asset. The Company allocates the purchase price to the assets acquired based upon their relative values.
Contingencies	Contingencies The Company is subject to a range of claims, lawsuits, and administrative proceedings that arise in the ordinary course of business. The Company accrues a liability (which amount includes litigation costs expected to be incurred) and charges operations for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated, in accordance with the recognition criteria of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 450, Contingencies
Revenue Recognition and Shipping and Handling Costs	Revenue Recognition In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which, along with subsequent ASUs, amended the existing accounting standards for revenue recognition (“Topic 606”). This guidance is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled to receive when products are transferred to customers. ASU 2014-09 was effective for the Company beginning January 1, 2019. The majority of the Company’s contracts with customers generally consist of a single performance obligation to transfer promised goods. Based on the Company’s evaluation and review of its contracts with customers, the timing and amount of revenue recognized based on ASU 2014-09 is consistent with the Company’s revenue recognition policy under previous guidance. The Company has therefore concluded that the adoption of ASU 2014-09 did not have a material impact on its financial position, results of operations, or cash flows. The Company’s revenues are generated through sales of its products to distributors or customers. Revenue is recognized at the point in which the performance obligation under the terms of a contract with the customer have been satisfied and control has transferred. The Company’s performance obligation is typically defined as the accepted purchase order, the direct-to-consumer order, or the contract with the customer which requires the Company to deliver the requested products at agreed upon prices at the time and location of the customer’s choice. The Company generally does not offer warranties or a right to return on the products it sells except in the instance of a product recall or other limited circumstances. Revenue is measured as the amount of consideration the Company expects to receive in exchange for fulfilling the performance obligation. Sales and other taxes the Company collects concurrent with the sale of products are excluded from revenue. The Company's normal payment terms vary by the type and location of its customers and the products offered. The time between invoicing and when payment is due is not significant. None of the Company's customer contracts as of December 31, 2021 contains a significant financing component. The Company routinely offers sales discounts and promotions through various programs to its customers and consumers. These programs include rebates, temporary on-shelf price reductions, off-invoice discounts, retailer advertisements, product coupons and other trade activities. Provision for discounts and incentives are recorded in the same period in which the related revenues are recognized. At the end of each accounting period, the Company recognizes a liability for estimated sales discounts that have been incurred but not paid which totaled $3.6 million as of December 31, 2021 and 2020. The offsetting charge is recorded as a reduction of revenues in the same period when the expense is incurred. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. The incremental cost to obtain contracts was not material. Presentation of Net Revenues by Channel
Earnings (Loss) Per Share	Earnings (Loss) Per Share Earnings (loss) per share (“EPS”) represents net income available to common stockholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS represents net income available to common stockholders divided by the weighted-average number of common shares outstanding, inclusive of the dilutive impact of potential common shares outstanding during the period. Such potential common shares include options, unvested restricted stock, restricted stock units (“RSUs”), contracts classified as assets or liabilities that are required or assumed to be share-settled under the two-class method, warrants and convertible preferred stock. The Company calculates basic and diluted EPS available to common stockholders in conformity with the two-class method required for companies with participating securities. Pursuant to ASU 2020-06, the Company applies the more dilutive of the if-converted method and the two-class method to its Notes. The Company considers all series of convertible preferred stock issued and outstanding prior to the IPO to be participating securities. Under the two-class method, the net loss available to common stockholders was not allocated to the convertible preferred stock as the holders of convertible preferred stock issued and outstanding prior to the IPO did not have a contractual obligation to share in losses. Computation of EPS for the years ended December 31, 2021 and 2020 also excludes adjustments under the two-class method relating to a liability classified, share-settled obligation to an executive officer to deliver a variable number of shares based on a fixed monetary amount because the shares to be delivered are not participating securities as they do not have voting rights and are not entitled to participate in dividends until they are issued. Nonvested restricted stock awards (referred to as participating securities) are excluded from the dilutive impact of common equivalent shares outstanding in accordance with authoritative guidance under the two-class method. The nonvested restricted stockholders are entitled to participate in dividends declared on common stock as if the shares were fully vested and hence nonvested restricted stock shares are deemed to be participating securities. Under the two-class method, net income, but not net loss, available to nonvested restricted stockholders is excluded from net income available to common stockholders for purposes of
Prepaid Expenses	Prepaid Expenses Prepaid expenses primarily include prepaid rent and insurance, which are expensed in the period to which they relate.
Investment in Joint Venture	Investment in Joint VentureThe Company uses the equity method of accounting to record transactions associated with its joint venture when the Company shares in joint control of the investee. Investment in joint venture is not consolidated but is recorded in “Investment in unconsolidated joint venture” in the Company’s consolidated balance sheet. The Company recognizes its portion of the investee’s results in “Equity in losses of unconsolidated joint venture” in its consolidated statement of operations.
Selling, General and Administrative (“SG&A”) Expenses	Selling, General and Administrative (“SG&A”) ExpensesSG&A expenses are primarily comprised of selling, marketing expenses and administrative expenses, share-based compensation, outbound shipping and handling costs, non-manufacturing rent expense, depreciation and amortization expense on non-manufacturing assets and other non-production operating expenses. Selling and marketing expenses include share-based compensation awards to brand ambassadors, advertising costs, costs associated with consumer promotions, product samples and sales aids incurred to acquire new customers, retain existing customers and build brand awareness. Administrative expenses include the expenses related to management, accounting, legal, IT, and other office functions. Advertising costs are expensed as incurred. Advertising costs in the years ended December 31, 2021, 2020 and 2019 were $12.1 million, $0.3 million and $0.3 million, respectively. Non-advertising related components of the Company’s total marketing expenditures primarily include costs associated with consumer promotions, product sampling and sales aids, which are also included in SG&A.
Research and Development	Research and DevelopmentResearch and development costs, which includes enhancements to existing products and new product development, are expensed in the period incurred. Research and development expenses primarily consist of personnel and related expenses for the Company’s research and development staff, including salaries, benefits, bonuses, and share-based compensation, scale-up expenses, and depreciation and amortization expense on research and development assets. Future research and development expenses will include expenses associated with the Company’s new Commerce, California commercialization center.
Share-Based Compensation	Share-Based Compensation The Company measures all share-based compensation cost at the grant date, based on the fair values of the awards that are ultimately expected to vest, and recognizes that cost as an expense in its consolidated statements of operations over the requisite service period. The Company estimates the fair value of option awards using the Black-Scholes option valuation model, which requires management to make certain assumptions for estimating the fair value of stock options at the date of grant including the fair value and projected volatility of the underlying common stock and the expected term of the award. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. Because the Company’s stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimates, in management’s opinion, the existing models may not necessarily provide a reliable single measure of the fair value of the Company’s stock options. Although the fair value of stock options is determined using an option valuation model, that value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction.
Employee Benefit Plan	Employee Benefit PlanOn January 1, 2017 the Company initiated a 401(k) retirement saving plan (“401-K Plan”) for the benefit of eligible employees. Under terms of this plan, eligible employees are able to make contributions of their wages on a tax-deferred basis.
Restructuring Plan	Restructuring Plan The Company accounts for exit or disposal activities in accordance with ASC 420, “Exit or Disposal Cost Obligations.” The Company defines a business restructuring as an exit or disposal activity that includes but is not limited to a program which is planned and controlled by management and materially changes either the scope of a business or the manner in which that business is conducted. Business restructuring charges may include (i) contract termination costs and (ii) other related costs associated with exit or disposal activities.
Recently Adopted and New Accounting Pronouncements	Recently Adopted Accounting Pronouncements On December 18, 2019, the FASB issued ASU No. 2019-12, “Simplifying the Accounting for Income Taxes (Topic 740)” (“ASU 2019-12”). ASU 2019-12 eliminates the need for an organization to analyze whether the following apply in a given period (1) exceptions to the incremental approach for intra-period tax allocation, (2) exceptions to accounting for basis differences when there are ownership changes in foreign investments, and (3) exceptions in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also is designed to improve financial statement preparers’ application of income tax-related guidance and simplify GAAP for (1) franchise taxes that are partially based on income, (2) transactions with a government that result in a step-up in the tax basis of goodwill, (3) separate financial statements of legal entities that are not subject to tax, and (4) enacted changes in tax laws in interim periods. For public business entities, the amendments in ASU 2019-12 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted ASU 2019-12 on January 1, 2021. Adoption of ASU 2019-12 did not result in any material changes to the way the tax provision is prepared and did not have a material impact on the Company’s financial position, results of operations or cash flows. On August 5, 2020, the FASB issued ASU No. 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity” (“ASU 2020-06”). ASU 2020-06 simplifies accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity, by removing certain separation models that require the separation of a convertible debt instrument into a debt component and an equity or derivative component. ASU 2020-06 removes from U.S. GAAP the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. After adoption of ASU 2020-06 entities will not separately present in equity an embedded conversion feature in such debt. Instead entities will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (2) a convertible instrument was issued at a substantial premium. ASU 2020-06 also expands disclosure requirements for convertible instruments and simplifies areas of the guidance for diluted earnings-per-share calculations that are impacted by the amendments. Under ASU 2020-06, entities must apply the more dilutive of the if-converted method and the two-class method to all convertible instruments; the treasury stock method is no longer available. ASU 2020-06 eliminates an entity’s ability to overcome the presumption of share settlement, and as a result, the issuers of convertible debt that may be settled in any combination of cash or stock at the issuer’s option, must use the more dilutive among the if-converted method and the two-class method in computing diluted net income per share, which is typically more dilutive than the net share settlement under the treasury stock method. ASU 2020-06 is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted. The Company early adopted ASU 2020-06 in the first quarter of 2021 concurrent with the issuance of its Notes. There were no changes to the Company’s previously issued financial statements since the Company had no existing convertible notes prior to issuance of the Notes in the first quarter of 2021. Upon adoption of ASU 2020-06, the Company recorded the issuance of the Notes at their face value net of issuance costs in long-term liabilities and the value of the capped call options in APIC. See Note 8 . New Accounting Pronouncements None.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of property, plant, and equipment	Property, plant and equipment are carried at cost less accumulated depreciation and are depreciated using the straight-line method over the following estimated useful lives: Land Not amortized Buildings 30 years Leasehold improvements Shorter of lease term or estimated useful life Furniture and fixtures 3 years Manufacturing equipment 5 to 10 years Research and development equipment 5 to 10 years Software and computer equipment 3 years Vehicles 5 years December 31, (in thousands) 2021 2020 Manufacturing equipment $ 115,412 $ 62,521 Research and development equipment 16,837 12,342 Leasehold improvements 20,250 9,277 Building 22,937 12,569 Finance leases 867 212 Software 1,297 402 Furniture and fixtures 868 614 Vehicles 584 377 Land 5,434 3,995 Assets not yet placed in service 95,455 46,148 Total property, plant and equipment $ 279,941 $ 148,457 Less: accumulated depreciation and amortization 53,452 33,158 Property, plant and equipment, net $ 226,489 $ 115,299
Summary of disaggregation of revenue	Effective January 1, 2020, the Company began presenting net revenues by geography and distribution channel as follows: Distribution Channel Description U.S. Retail Net revenues from retail sales to the U.S. market (1) U.S. Foodservice Net revenues from restaurant and foodservice sales to the U.S. market International Retail Net revenues from retail sales to international markets, including Canada International Foodservice Net revenues from restaurant and foodservice sales to international markets, including Canada ____________ (1) Includes net revenues from direct-to-consumer sales. The following table presents the Company’s net revenues by channel: Year Ended December 31, 2021 2020 2019 (in thousands) U.S.: Retail $ 243,360 $ 264,111 $ 129,383 Foodservice 76,475 60,763 70,372 U.S. net revenues 319,835 324,874 199,755 International: Retail 81,483 36,472 15,426 Foodservice 63,382 45,439 82,716 International net revenues 144,865 81,911 98,142 Net revenues $ 464,700 $ 406,785 $ 297,897

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Components of lease	Lease costs for operating and finance leases were as follows: (in thousands) Statement of Operations Location Year Ended December 31, 2021 Year Ended December 31, 2020 Operating lease cost: Lease cost Cost of goods sold $ 2,583 $ 1,570 Lease cost Research and development expenses 652 621 Lease cost Selling, general and administrative expenses 961 569 Variable lease cost (1) Cost of goods sold 40 17 Operating lease cost $ 4,236 $ 2,777 Short-term lease cost Selling, general and administrative expenses $ 222 $ 311 Finance lease cost: Amortization of right-of use assets Cost of goods sold $ 177 75 Interest on lease liabilities Interest expense — $ 13 Finance lease cost $ 177 $ 88 Total lease cost (2) $ 4,635 $ 3,176 ____________ (1) Variable lease cost primarily consists of common area maintenance, such as cleaning and repairs. (2) Excludes Campus Lease. Weighted average remaining lease terms and weighted average discount rates were: December 31, 2021 Operating Leases (1) Finance Leases Weighted average remaining lease term (years) 8.4 3.6 Weighted average discount rate 4.4 % 2.3 % ____________ (1) Excludes Campus Lease.
Schedule of supplemental balance sheet information	Supplemental balance sheet information related to leases are as follows: (in thousands) Balance Sheet Location December 31, 2021 December 31, 2020 Assets (1) Operating leases Operating lease right-of-use assets $ 26,815 $ 14,570 Finance leases, net Property, plant and equipment, net 615 212 Total lease assets $ 27,430 $ 14,782 Liabilities (1) Current: Operating lease liabilities Current portion of operating lease liabilities $ 4,458 $ 3,095 Finance lease liabilities Current portion of finance lease liabilities 182 71 Long-term: Operating lease liabilities Operating lease liabilities, net of current portion 22,599 11,793 Finance lease liabilities Finance lease obligations and other long-term liabilities 442 149 Total lease liabilities $ 27,681 $ 15,108 ____________ (1) Excludes Campus Lease.
Schedule of future maturities of operating lease liabilities	The following is a schedule by year of the maturities of lease liabilities with original terms in excess of one year, as of December 31, 2021: December 31, 2021 (in thousands) Operating Leases (1) Finance Leases 2022 $ 5,548 $ 194 2023 5,288 181 2024 3,543 147 2025 2,970 115 2026 2,831 9 Thereafter 12,984 — Total undiscounted future minimum lease payments 33,164 646 Less imputed interest (6,107) (22) Total discounted future minimum lease payments $ 27,057 $ 624 ____________ (1) Excludes Campus Lease.
Schedule of future maturities of finance lease liabilities	The following is a schedule by year of the maturities of lease liabilities with original terms in excess of one year, as of December 31, 2021: December 31, 2021 (in thousands) Operating Leases (1) Finance Leases 2022 $ 5,548 $ 194 2023 5,288 181 2024 3,543 147 2025 2,970 115 2026 2,831 9 Thereafter 12,984 — Total undiscounted future minimum lease payments 33,164 646 Less imputed interest (6,107) (22) Total discounted future minimum lease payments $ 27,057 $ 624 ____________ (1) Excludes Campus Lease.

Asset Acquisition (Tables)

Asset Acquisition (Tables)	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of asset acquisition	The following table details the purchase price allocation of the acquired assets based on their relative fair values as of the acquisition date: (in thousands) Manufacturing equipment $ 1,273 Building 9,576 Land 2,774 Assembled workforce (1) 1,859 Total $ 15,482 _____________ (1) Assembled workforce is recorded in “Other non-current assets, net” in the consolidated balance sheet and will be amortized over an estimated useful life of approximately 2.0 years.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Major classes of inventory	Major classes of inventory were as follows: December 31, (in thousands) 2021 2020 Raw materials and packaging $ 129,974 $ 83,702 Work in process 50,227 12,887 Finished goods 61,669 25,128 Total $ 241,870 $ 121,717

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property, plant, and equipment	Property, plant and equipment are carried at cost less accumulated depreciation and are depreciated using the straight-line method over the following estimated useful lives: Land Not amortized Buildings 30 years Leasehold improvements Shorter of lease term or estimated useful life Furniture and fixtures 3 years Manufacturing equipment 5 to 10 years Research and development equipment 5 to 10 years Software and computer equipment 3 years Vehicles 5 years December 31, (in thousands) 2021 2020 Manufacturing equipment $ 115,412 $ 62,521 Research and development equipment 16,837 12,342 Leasehold improvements 20,250 9,277 Building 22,937 12,569 Finance leases 867 212 Software 1,297 402 Furniture and fixtures 868 614 Vehicles 584 377 Land 5,434 3,995 Assets not yet placed in service 95,455 46,148 Total property, plant and equipment $ 279,941 $ 148,457 Less: accumulated depreciation and amortization 53,452 33,158 Property, plant and equipment, net $ 226,489 $ 115,299

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of debt balances	The following is a summary of debt balances as of December 31, 2021 and December 31, 2020: (in thousands) December 31, December 31, Convertible senior notes $ 1,150,000 $ — Revolving credit facility — 25,000 Debt issuance costs (20,326) — Total debt outstanding $ 1,129,674 $ 25,000 Less: current portion of long-term debt — 25,000 Long-term debt $ 1,129,674 $ — The following is a summary of the Company’s Notes as of December 31, 2021: (in thousands) Principal Amount Unamortized Issuance Costs Net Carrying Amount Fair Value Amount Leveling 0% Convertible senior notes due on March 15, 2027 $ 1,150,000 $ 20,326 $ 1,129,674 $ 809,186 Level 2

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Summary of shares available for grant	The following table summarizes the shares available for grant under the 2018 Plan: Shares Available for Grant Balance - December 31, 2020 5,021,270 Authorized 2,144,521 Granted (1,038,429) Shares withheld to cover taxes 25,863 Forfeited 362,582 Balance - December 31, 2021 6,515,807
Schedule of fair value assumptions	Following are the assumptions used in the Black-Scholes valuation model for options granted during the periods shown below: Year Ended December 31, 2021 2020 2019 Risk-free interest rate 1.4% 1.3% 2.3% Average expected term (years) 7.0 7.0 6.1 Expected volatility 55.7% 55.0% 55.0% Dividend yield — — —
Schedule of stock option activity	The following table summarizes the Company’s stock option activity during the period from December 31, 2017 through December 31, 2021: Number Weighted Weighted Aggregate Intrinsic Value (in thousands) (1) Outstanding at December 31, 2018 5,120,293 $ 3.13 7.3 $ 81,371 Granted 1,571,925 $ 39.01 — $ — Exercised (1,429,756) $ 1.87 — $ 121,591 Cancelled/Forfeited (91,486) $ 9.33 — $ — Outstanding at December 31, 2019 5,170,976 $ 14.28 7.5 $ 329,879 Granted 268,193 $ 99.74 — $ — Exercised (1,163,374) $ 7.75 — $ 132,935 Cancelled/Forfeited (57,517) $ 37.14 — $ — Outstanding at December 31, 2020 4,218,278 $ 21.20 6.6 $ 443,595 Granted 475,520 $ 91.42 — $ — Exercised (485,016) $ 16.76 — $ 51,901 Cancelled/Forfeited (252,418) $ 70.41 — $ — Outstanding at December 31, 2021 3,956,364 $ 27.04 5.9 $ 180,302 Vested and exercisable at December 31, 2021 2,905,712 $ 14.20 5.0 $ 159,882 Vested and expected to vest at December 31, 2021 3,622,946 $ 22.34 5.6 $ 178,657 __________ (1) Aggregate intrinsic value is calculated as the difference between the value of common stock on the transaction date and the exercise price multiplied by the number of shares issuable under the stock option. Aggregate intrinsic value of shares outstanding at the beginning and end of the reporting period is calculated as the difference between the value of common stock on the beginning and end dates, respectively, and the exercise price multiplied by the number of shares outstanding.
Schedule of RSU activity	The following table summarizes the Company’s RSU activity from December 31, 2019 through December 31, 2021: Number of Units Weighted Unvested at December 31, 2019 149,004 $ 132.73 Granted 244,752 $ 109.61 Vested (99,970) $ 127.71 Cancelled/Forfeited (17,797) $ — Unvested at December 31, 2020 275,989 $ 114.99 Granted 562,909 $ 86 Vested (120,599) $ 123 Cancelled/Forfeited (110,124) $ — Unvested at December 31, 2021 608,175 $ 89
Schedule of restricted stock activity	The following table summarizes the Company’s restricted stock activity: Number Weighted Weighted Unvested at December 31, 2019 88,988 1.2 19.49 Granted 0 — — Vested/Released (76,804) — 19.97 Cancelled/Forfeited — — — Unvested at December 31, 2020 12,184 0.3 20.02 Granted — — — Vested/Released (12,184) — 20.02 Cancelled/Forfeited — — — Unvested at December 31, 2021 — — —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of components of income tax expense	The provision for income taxes was as follows: (in thousands) Year Ended December 31, Current: 2021 2020 2019 Federal $ — $ — $ — State 60 72 9 $ 60 $ 72 $ 9 Deferred: Federal $ — $ — $ — State — — — $ — $ — $ — Provision for income tax $ 60 $ 72 $ 9
Schedule of effective income tax rate reconciliation	A reconciliation of income tax expense from continuing operations to the amount computed by applying the statutory federal income tax rate to the net loss from continuing operations is summarized as follows: Year Ended December 31, (in thousands) 2021 2020 2019 U.S. income tax at federal statutory rate $ (38,229) $ (11,063) $ (2,611) State income tax, net of federal benefits (4,991) (1,962) (2,550) Foreign rate differential (985) (54) — Stock warrant liability — — 2,626 Share-based compensation (4,932) (21,007) (21,236) Research and development credits (20) (10) (8) Change in tax rates (719) 2,989 73 Other 771 529 (98) Change in valuation allowance 49,165 30,650 23,813 Provision for income tax $ 60 $ 72 $ 9
Schedule of deferred tax assets and liabilities	Significant components of the Company's deferred tax assets and liabilities as of December 31, 2021, and 2020 are shown below. December 31, (in thousands) 2021 2020 Deferred Tax Assets: Net operating loss (NOL) $ 128,006 $ 78,464 Intangibles 1,308 1,495 Share-based compensation 4,584 3,295 Interest 388 311 Inventory reserve 2,139 2,262 Other 1,820 2,024 Total gross deferred tax assets 138,245 87,851 Deferred Tax liabilities: Property, plant and equipment 3,056 1,773 Other — — Total gross deferred tax liabilities 3,056 1,773 Valuation allowance 135,189 86,078 Net deferred tax assets (liabilities) $ — $ —
Schedule of unrecognized tax benefits	The following table summarizes the activity related to the Company’s gross unrecognized tax benefits at the beginning and end of the years ended December 31, 2021 and 2020: Year Ended December 31, (in thousands) 2021 2020 Gross unrecognized tax benefits at the beginning of the year $ 5,399 $ 3,336 Increases related to current year positions 3,462 2,063 Increases/Decreases related to prior year positions — — Expiration of unrecognized tax benefits — — Gross unrecognized tax benefits at the end of the year $ 8,861 $ 5,399

Net Loss Per Share Available _2

Net Loss Per Share Available to Common Stockholders (“EPS”) (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of basic and diluted net loss per common share	(in thousands, except share and per share amounts) Year Ended December 31, 2021 2020 2019 Numerator: Net loss available to common stockholders $ (182,105) $ (52,752) $ (12,443) Undistributed net income available to unvested restricted stockholders — — — Net loss available to common stockholders—basic $ (182,105) $ (52,752) $ (12,443) Denominator: Weighted average common shares outstanding—basic 63,172,368 62,290,445 42,274,777 Dilutive effect of shares issuable under stock options — — — Dilutive effect of RSUs — — — Dilutive effect of share-settled obligation — — — Dilutive effect of Notes, if converted (1) — — — Weighted average common shares outstanding—diluted 63,172,368 62,290,445 42,274,777 Net loss per share available to common stockholders—basic $ (2.88) $ (0.85) $ (0.29) ______________ (1) As the Company recorded a net loss in the year ended December 31, 2021, inclusion of shares from the conversion premium or spread would be anti-dilutive. The Company had no Notes outstanding during the years ended December 31, 2020 and 2019.
Schedule of antidilutive securities excluded from computation of earnings per share	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share available to common stockholders for the periods presented because the impact of including them would have been antidilutive: Year Ended December 31, 2021 2020 2019 Options to purchase common stock 3,956,364 4,218,278 5,170,976 Restricted stock units 608,175 275,989 149,004 Total 4,564,539 4,494,267 5,319,980

Introduction (Details)

Introduction (Details) $ / shares in Units, ft² in Thousands, $ in Millions	Aug. 05, 2019USD ($)$ / sharesshares	May 06, 2019USD ($)$ / sharesshares	Dec. 31, 2021	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)	Oct. 02, 2021ft²
Subsidiary, Sale of Stock [Line Items]
Area leased (in square feet) | ft²						64
United States | Long-lived assets | Geographic Concentration Risk
Subsidiary, Sale of Stock [Line Items]
Concentration risk			90.00%
Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of common stock shares converted (in shares) | shares				41,562,111
IPO
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares		11,068,750
Sale of stock, price per share (in dollars per share) | $ / shares		$ 25
Proceeds from IPO, net		$ 252.4
Underwriting discounts and commissions		19.4
Sale of stock, issuance costs		$ 4.9
Number of common stock shares converted (in shares) | shares		41,562,111
Number of shares issued for each share of convertible preferred stock converted (in shares) | shares		1
Payments of deferred offering costs				$ 2.5	$ 2.4
Deferred offering costs				$ 4.9	$ 4.9
IPO | Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of common stock shares converted (in shares) | shares				11,068,750
Number of shares able to purchase (in shares) | shares		160,767
Secondary Offering
Subsidiary, Sale of Stock [Line Items]
Sale of stock, price per share (in dollars per share) | $ / shares	$ 160
Proceeds from IPO, net	$ 37.4
Underwriting discounts and commissions	1.5
Sale of stock, issuance costs	$ 1.1
Number of shares issued (in shares) | shares	3,487,500
Payments of deferred offering costs				$ 2.2
Deferred offering costs				$ 1.1
Secondary Offering | Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of common stock shares converted (in shares) | shares				250,000
Over-allotment option
Subsidiary, Sale of Stock [Line Items]
Number of shares issued (in shares) | shares	250,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details)	Apr. 08, 2019USD ($)	Dec. 31, 2016USD ($)	Feb. 28, 2016USD ($)shares	Oct. 31, 2015USD ($)	Dec. 31, 2021USD ($)segmentbusinessshares	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)shares	Mar. 12, 2021USD ($)	Mar. 05, 2021USD ($)	May 06, 2019shares	May 05, 2019$ / sharesshares
Class of Warrant or Right [Line Items]
Number of operating segments | segment					1
Number of reportable segments | segment					1
Debt issuance costs					$ 20,326,000	$ 0
Foreign currency translation (loss) gain, net of tax					(2,301,000)	1,748,000	$ 0
Realized and unrealized foreign currency (losses ) gains					(200,000)	200,000	0
Allowance for doubtful accounts					$ 1,300,000	0
Number of businesses acquired | business					1
Impairment write-off of long-lived assets					$ 0	0	0
Accrued stock issuance costs					0	0
Liability for estimated sales discounts					3,600,000	3,600,000
Advertising costs					12,100,000	300,000	300,000
Cost of goods sold					347,419,000	284,510,000	198,141,000
Research and development expenses					66,946,000	31,535,000	20,650,000
Matching contribution					$ 1,500,000	$ 700,000	$ 200,000
Stock options granted (in shares) | shares					475,520		268,193	1,571,925
Gigi Pritzker Pucker | Beyond Meat, Inc
Class of Warrant or Right [Line Items]
Ownership interest					5.00%	5.00%
Money Market Accounts
Class of Warrant or Right [Line Items]
Cash equivalents, concentration					90.00%
Demand Deposits
Class of Warrant or Right [Line Items]
Cash equivalents, concentration					10.00%
Convertible Debt
Class of Warrant or Right [Line Items]
Debt issuance costs					$ 23,600,000	$ 0				$ 23,600,000
Debt issuance costs, unpaid					$ 0
Convertible Debt | Convertible Senior Notes Due 2027
Class of Warrant or Right [Line Items]
Debt, face amount										$ 1,000,000,000
Stated rate					0.00%					0.00%
Debt issuance costs					$ 20,326,000
Convertible Debt | Additional Convertible Senior Notes Due 2027
Class of Warrant or Right [Line Items]
Debt, face amount									$ 150,000,000
Series B
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares) | shares												121,694
Exercise price (in dollars per share) | $ / shares												$ 1.07
Series E
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares) | shares												39,073
Exercise price (in dollars per share) | $ / shares												$ 3.68
IPO
Class of Warrant or Right [Line Items]
Deferred offering costs							$ 4,900,000	$ 4,900,000
Deferred offering costs, incurred and paid							2,500,000	2,400,000
IPO | Common Stock
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares) | shares											160,767
Secondary Offering
Class of Warrant or Right [Line Items]
Deferred offering costs							1,100,000
Deferred offering costs, incurred and paid							2,200,000
Shipping and Handling
Class of Warrant or Right [Line Items]
Cost of goods sold					$ 19,100,000	$ 11,900,000	$ 10,900,000
Distributor One | Customer Concentration Risk | Revenue Benchmark
Class of Warrant or Right [Line Items]
Concentration risk					12.00%		17.00%
Distributor Two | Customer Concentration Risk | Revenue Benchmark
Class of Warrant or Right [Line Items]
Concentration risk					11.00%		16.00%
Customer One | Customer Concentration Risk | Revenue Benchmark
Class of Warrant or Right [Line Items]
Concentration risk						13.00%
Consulting Agreement | Executive Chair
Class of Warrant or Right [Line Items]
Monthly transaction amount	$ 20,210.33
Consulting fees, related party						$ 60,631	$ 265,548
Consulting Agreement | Affiliated Entity | Cleveland Avenue, LLC
Class of Warrant or Right [Line Items]
Due to affiliate					$ 1,000,000	0	0
Bonus | Executive Chair
Class of Warrant or Right [Line Items]
Consulting fees, related party						121,260
Advisor Agreement | Affiliated Entity
Class of Warrant or Right [Line Items]
Daily transaction amount				$ 4,000
Amended Advisor Agreement | Affiliated Entity
Class of Warrant or Right [Line Items]
Monthly transaction amount		$ 10,000	$ 25,000
Consulting fees, related party							$ 120,000	$ 140,000
Legal Services | Affiliated Entity
Class of Warrant or Right [Line Items]
Consulting fees, related party					15,700,000	11,100,000
Due to affiliate					2,200,000
Non-qualified Stock Option | Amended Advisor Agreement | Affiliated Entity
Class of Warrant or Right [Line Items]
Stock options granted (in shares) | shares			532,590
Vesting period			3 years
Common Stock
Class of Warrant or Right [Line Items]
Share-based compensation liability					$ 0	$ 1,000,000
Minimum | Amended Advisor Agreement | Affiliated Entity
Class of Warrant or Right [Line Items]
Days of service		5 days
Maximum | Amended Advisor Agreement | Affiliated Entity
Class of Warrant or Right [Line Items]
Days of service		6 days
SVB Credit Facilities | Common Stock | Line of Credit
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares) | shares												60,002
Exercise price (in dollars per share) | $ / shares												$ 3

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of property, plant, and equipment (Details)	12 Months Ended
	Dec. 31, 2021
Buildings
Property, Plant and Equipment [Line Items]
Estimated useful life	30 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Manufacturing equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Manufacturing equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Research and development equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years
Research and development equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Software
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Vehicles
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of net revenues by platform and channel (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Net revenues	$ 464,700	$ 406,785	$ 297,897
U.S. net revenues
Disaggregation of Revenue [Line Items]
Net revenues	319,835	324,874	199,755
International net revenues
Disaggregation of Revenue [Line Items]
Net revenues	144,865	81,911	98,142
Retail | U.S. net revenues
Disaggregation of Revenue [Line Items]
Net revenues	243,360	264,111	129,383
Retail | International net revenues
Disaggregation of Revenue [Line Items]
Net revenues	81,483	36,472	15,426
Foodservice | U.S. net revenues
Disaggregation of Revenue [Line Items]
Net revenues	76,475	60,763	70,372
Foodservice | International net revenues
Disaggregation of Revenue [Line Items]
Net revenues	$ 63,382	$ 45,439	$ 82,716

Restructuring (Details)

Restructuring (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 15,794	$ 6,430	$ 4,869
Contract Termination
Restructuring Cost and Reserve [Line Items]
Accrued unpaid liabilities, contract termination	$ 2,700	$ 800

Leases - Narrative (Details)

Leases - Narrative (Details) ft² in Thousands, $ in Millions	Jan. 14, 2021renewal_option	Oct. 30, 2020USD ($)	Oct. 02, 2021USD ($)ft²	Dec. 31, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Lease not yet commenced, term of contract	12 years
Number of renewal options, lease not yet commenced | renewal_option	2
Lease not yet commenced, renewal term	5 years
Consideration transferred		$ 15.5
Area leased (in square feet) | ft²			64
Renewal term			60 months
Leased Property
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Consideration transferred			$ 10.4
Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Lease, initial term				2 years
Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Lease, initial term				12 years

Leases - Components of lease (D

Leases - Components of lease (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Lease Cost
Variable lease cost	$ 40	$ 17
Operating lease cost	4,236	2,777
Short-term lease cost	222	311
Amortization of right-of use assets	177	75
Interest on lease liabilities	0	13
Finance lease cost	177	88
Total lease cost(2)	$ 4,635	3,176
Operating Leases
Weighted average remaining lease term (years)	8 years 4 months 24 days
Weighted average discount rate	4.40%
Finance Leases
Weighted average remaining lease term (years)	3 years 7 months 6 days
Weighted average discount rate	2.30%
Cost of goods sold
Lease Cost
Lease cost	$ 2,583	1,570
Research and development expenses
Lease Cost
Lease cost	652	621
Selling, general and administrative expenses
Lease Cost
Lease cost	$ 961	$ 569

Leases - Schedule of supplement

Leases - Schedule of supplemental balance sheet information (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Assets
Operating lease right-of-use assets	$ 26,815	$ 14,570
Finance lease, right-of-use asset, statement of financial position	Property, plant and equipment, net	Property, plant and equipment, net
Finance leases, net	$ 615	$ 212
Total lease assets	27,430	14,782
Current:
Current portion of operating lease liabilities	4,458	3,095
Finance lease liabilities	182	71
Long-term:
Operating lease liabilities	22,599	11,793
Finance lease obligations and other long term liabilities	442	149
Total lease liabilities	$ 27,681	$ 15,108
Finance lease liability, noncurrent, statement of financial position	Finance lease obligations and other long term liabilities	Finance lease obligations and other long term liabilities

Leases - Schedule of future mat

Leases - Schedule of future maturities of lease liabilities (Details) $ in Thousands	Dec. 31, 2021USD ($)
Operating Leases(1)
2022	$ 5,548
2023	5,288
2024	3,543
2025	2,970
2026	2,831
Thereafter	12,984
Total undiscounted future minimum lease payments	33,164
Less imputed interest	(6,107)
Total discounted future minimum lease payments	27,057
Finance Leases
2022	194
2023	181
2024	147
2025	115
2026	9
Thereafter	0
Total undiscounted future minimum lease payments	646
Less imputed interest	(22)
Total discounted future minimum lease payments	$ 624

Asset Acquisition - Narrative (

Asset Acquisition - Narrative (Details) $ in Thousands	Oct. 30, 2020USD ($)employee	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Business Combination and Asset Acquisition [Abstract]
Consideration transferred	$ 15,500
Payments to acquire productive assets	14,500	$ 0	$ 15,482	$ 0
Acquisition costs	$ 1,000
Number of employees hired | employee	180

Asset Acquisition - Schedule of

Asset Acquisition - Schedule of allocation of purchase consideration (Details) $ in Thousands	Oct. 30, 2020USD ($)
Property, Plant and Equipment [Line Items]
Assembled workforce	$ 1,859
Total	$ 15,482
Assembled workforce, useful life	2 years
Manufacturing equipment
Property, Plant and Equipment [Line Items]
Tangible assets	$ 1,273
Building
Property, Plant and Equipment [Line Items]
Tangible assets	9,576
Land
Property, Plant and Equipment [Line Items]
Tangible assets	$ 2,774

Inventories - Schedule of major

Inventories - Schedule of major classes of inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials and packaging	$ 129,974	$ 83,702
Work in process	50,227	12,887
Finished goods	61,669	25,128
Total	$ 241,870	$ 121,717

Inventories - Narrative (Detail

Inventories - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventory write-down	$ 12.5	$ 10.8	$ 6.4
Write down of inventory to lower of cost or net realizable value	$ 0.8	$ 0

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of property, plant, and equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Finance leases	$ 867	$ 212
Total property, plant and equipment	279,941	148,457
Less: accumulated depreciation and amortization	53,452	33,158
Property, plant and equipment, net	226,489	115,299
Manufacturing equipment
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	115,412	62,521
Research and development equipment
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	16,837	12,342
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	20,250	9,277
Buildings
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	22,937	12,569
Software
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	1,297	402
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	868	614
Vehicles
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	584	377
Land
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	5,434	3,995
Assets not yet placed in service
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 95,455	$ 46,148

Property, Plant and Equipment_2

Property, Plant and Equipment - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 21,663,000	$ 13,299,000	$ 8,106,000
Assets held-for-sale	0	0
Note receivable	3,800,000
Cost of goods sold
Property, Plant and Equipment [Line Items]
Depreciation and amortization	17,700,000	10,100,000	5,700,000
Research and development expenses
Property, Plant and Equipment [Line Items]
Depreciation and amortization	3,700,000	3,100,000	2,400,000
Selling, general and administrative expenses
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 300,000	$ 100,000	$ 71,000

Debt - Schedule of debt balance

Debt - Schedule of debt balances (Details) - USD ($)	Dec. 31, 2021	Mar. 05, 2021	Feb. 25, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt issuance costs	$ (20,326,000)			$ 0
Total debt outstanding	1,129,674,000			25,000,000
Less: current portion of long-term debt	0			25,000,000
Long-term debt	1,129,674,000			0
Convertible Debt
Debt Instrument [Line Items]
Long-term debt, gross	1,150,000,000			0
Debt issuance costs	(23,600,000)	$ (23,600,000)		0
Revolving credit facility | Line of Credit
Debt Instrument [Line Items]
Long-term debt, gross	$ 0		$ 0	$ 25,000,000

Debt - Narrative (Details)

Debt - Narrative (Details)	Mar. 16, 2021USD ($)$ / shares	Mar. 12, 2021USD ($)	Mar. 05, 2021USD ($)day	Mar. 02, 2021USD ($)$ / shares	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Feb. 25, 2021USD ($)	Jan. 14, 2021USD ($)
Debt Instrument [Line Items]
Purchase of capped call options					$ 83,950,000	$ 0	$ 0
Debt issuance costs					20,326,000	0
Amortization of debt issuance costs					3,322,000	256,000	181,000
Capped call transactions, reduction to additional paid In capital					83,950,000
Prepaid and Other Current Assets
Debt Instrument [Line Items]
Debt issuance costs					0	1,100,000
Convertible Debt
Debt Instrument [Line Items]
Conversion price (in dollars per share) | $ / shares	$ 206
Net proceeds from debt			$ 1,000,000,000
Debt issuance costs			$ 23,600,000		23,600,000	0
Annual interest rate increase			0.50%
Conversion ratio			0.0048544
Debt default, cure period | day			30
Debt default, notice of default expiration period			60 days
Debt default, borrowing threshold amount			$ 100,000,000
Percentage of outstanding debt declarable			25.00%
Debt default, period of special interest			365 days
Amortization of debt issuance costs					$ 3,300,000	0
Remaining term					5 years 2 months 12 days
Debt, outstanding balance					$ 1,150,000,000	0
Convertible Debt | Convertible period one
Debt Instrument [Line Items]
Threshold trading days | day			5
Threshold consecutive trading days | day			10
Threshold percentage of stock price trigger			98.00%
Convertible Debt | Convertible period two
Debt Instrument [Line Items]
Threshold trading days | day			20
Threshold consecutive trading days | day			30
Threshold percentage of stock price trigger			130.00%
Line of Credit
Debt Instrument [Line Items]
Interest expense					300,000	2,100,000	2,200,000
Fair Value, Inputs, Level 2 | Recurring
Debt Instrument [Line Items]
Convertible notes, fair value					$ 809,186,000
Call option
Debt Instrument [Line Items]
Purchase of capped call options	$ 84,000,000
Capped call transactions, strike price (in dollars per share) | $ / shares				$ 279.32
Capped call transactions, premium				100.00%
Capped call transactions, reduction to additional paid In capital		$ 84,000,000
Convertible Senior Notes Due 2027 | Convertible Debt
Debt Instrument [Line Items]
Debt, face amount			$ 1,000,000,000
Stated rate			0.00%		0.00%
Premium percentage	47.50%
Debt issuance costs					$ 20,326,000
Debt, outstanding balance					1,150,000,000
Additional Convertible Senior Notes Due 2027 | Convertible Debt
Debt Instrument [Line Items]
Debt, face amount		150,000,000
Additional Convertible Senior Notes Due 2027 | Call option | Convertible Debt
Debt Instrument [Line Items]
Purchase of capped call options	$ 84,000,000
Base Capped Call Transactions | Call option | Convertible Debt
Debt Instrument [Line Items]
Purchase of capped call options				$ 73,000,000
Additional Capped Call Transactions | Call option | Convertible Debt
Debt Instrument [Line Items]
Purchase of capped call options		$ 11,000,000
Equipment Loan | Line of Credit
Debt Instrument [Line Items]
Interest expense					0	200,000	600,000
Debt, outstanding balance							$ 5,000,000
Revolving credit facility | Line of Credit
Debt Instrument [Line Items]
Amortization of debt issuance costs					41,000
Debt, outstanding balance					$ 0	25,000,000		$ 0
Remaining borrowing capacity						$ 0
Interest rate					3.50%
Letter of credit
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 12,500,000				$ 12,500,000

Debt - Convertible senior notes

Debt - Convertible senior notes (Details) - USD ($)	Dec. 31, 2021	Mar. 05, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Debt issuance costs	$ 20,326,000		$ 0
Total debt outstanding	1,129,674,000		25,000,000
Fair Value, Inputs, Level 2 | Recurring
Debt Instrument [Line Items]
Convertible notes, fair value	809,186,000
Convertible Debt
Debt Instrument [Line Items]
Debt, outstanding balance	1,150,000,000		0
Debt issuance costs	$ 23,600,000	$ 23,600,000	$ 0
Convertible Senior Notes Due 2027 | Convertible Debt
Debt Instrument [Line Items]
Stated rate	0.00%	0.00%
Debt, outstanding balance	$ 1,150,000,000
Debt issuance costs	20,326,000
Total debt outstanding	$ 1,129,674,000

Stockholders_ Equity (Deficit_2

Stockholders’ Equity (Deficit) and Convertible Preferred Stock (Details) - $ / shares	May 06, 2019	Dec. 31, 2021	Dec. 31, 2020	Aug. 05, 2019
Class of Stock [Line Items]
Common stock, authorized (in shares)	500,000,000	500,000,000	500,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Convertible preferred stock, authorized (in shares)	500,000
Convertible preferred stock, par value (in dollars per share)	$ 0.0001
Common stock, issued (in shares)		63,400,899	62,820,351
Common stock, outstanding (in shares)		63,400,899	62,820,351
IPO
Class of Stock [Line Items]
Number of common stock shares converted (in shares)	41,562,111
Number of shares issued for each share of convertible preferred stock converted (in shares)	1
Over-allotment option
Class of Stock [Line Items]
Common stock, par value (in dollars per share)				$ 0.0001
Number of shares issued (in shares)				250,000

Share-Based Compensation - Narr

Share-Based Compensation - Narrative (Details) - USD ($)	Oct. 31, 2019	Aug. 01, 2019	Apr. 30, 2019	Apr. 30, 2019	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2022	Jan. 01, 2021	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding (in shares)					4,218,278	3,956,364	4,218,278	5,170,976			5,120,293
Shares issued (in shares)						7,730,884	7,127,079
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued, unvested (in shares)					275,989	608,175	275,989	149,004
Share-based compensation expense						$ 12,600,000	$ 9,800,000	$ 3,700,000
Unrecognized compensation expense, period of recognition						1 year 6 months
Unrecognized share-based compensation expense						$ 26,900,000
Vested (in shares)						120,599	99,970
Granted (in shares)						562,909	244,752
Restricted stock price (in dollars per share)						$ 86	$ 109.61
Fair value per share (in dollars per share)					$ 114.99	$ 89	$ 114.99	$ 132.73
Restricted stock units | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						1 year
Restricted stock units | New Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						3 years
Restricted stock units | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						4 years	4 years
Restricted stock units | Employee | Executive Chair
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage						100.00%
Vesting period						3 months
Restricted stock units | Employee | Executive Officer One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						1 year
Restricted stock units | Employee | Executive Officer Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						2 years
Restricted stock units | Employee | Continuing Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						2 years
Vesting interval period						6 months
Restricted stock units | First Anniversary | Employee | New Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage						25.00%	25.00%
Restricted stock units | Thereafter | Employee | New Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						3 years	3 years
Employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense						$ 13,300,000	$ 13,100,000	$ 6,300,000
Unrecognized compensation expense						$ 18,500,000
Unrecognized compensation expense, period of recognition						1 year 6 months
Employee Stock Options | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						48 months	48 months
Employee Stock Options | Employee | Executive Chair
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	24 months	48 months				3 months
Employee Stock Options | Employee | Continuing Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						2 years
Vesting interval period						6 months
Employee Stock Options | First Anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage						25.00%	25.00%	25.00%
Employee Stock Options | Thereafter
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						3 years	3 years	3 years
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense accrued, not issued						$ 1,500,000	$ 3,000,000
Share-based compensation liability					$ 1,000,000	$ 0	$ 1,000,000
Vested (in shares)					20,872
Fair value of shares vested					$ 2,500,000
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued, unvested (in shares)					12,184	0	12,184	88,988
Shares issued (in shares)						0	0
Vesting period			24 months
Share-based compensation expense						$ 200,000	$ 1,400,000	$ 1,800,000
Unrecognized share-based compensation expense						$ 0
Vested (in shares)						12,184	76,804
Granted (in shares)				99,433		0	0
Restricted stock price (in dollars per share)				$ 20.02		$ 0	$ 0
Purchase price (in dollars per share)			$ 0.01	$ 0.01
Fair value per share (in dollars per share)					$ 20.02	$ 0	$ 20.02	$ 19.49
Weighted average remaining contractual life						0 years	3 months 18 days	1 year 2 months 12 days
2018 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance (in shares)						18,771,398				20,915,919
Additional shares authorized annually (in shares)						2,144,521
Percent of common stock outstanding, per year						4.00%
2018 ESPP | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance (in shares)										1,876,455
Additional shares authorized annually (in shares)						536,130
Percent of common stock outstanding, per year						1.00%
Period of additional shares authorized						10 years
2018 ESPP | Employee Stock | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance (in shares)									2,412,585

Share-Based Compensation - Summ

Share-Based Compensation - Summary of shares available for grant (Details) - 2018 Plan	12 Months Ended
	Dec. 31, 2021shares
Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant, Number of Shares [Roll Forward]
Shares available for grant, beginning balance (in shares)	5,021,270
Authorized (in shares)	2,144,521
Granted (in shares)	(1,038,429)
Shares withheld to cover taxes (in shares)	25,863
Forfeited (in shares)	362,582
Shares available for grant, ending balance (in shares)	6,515,807

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of fair value assumptions (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	1.40%	1.30%	2.30%
Average expected term (years)	7 years	7 years	6 years 1 month 6 days
Expected volatility	55.70%	55.00%	55.00%
Dividend yield	0.00%	0.00%	0.00%

Share-Based Compensation - Sc_2

Share-Based Compensation - Schedule of stock option activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Number of Stock Options
Outstanding, beginning balance (in shares)	4,218,278	5,170,976	5,120,293
Granted (in shares)	475,520		268,193	1,571,925
Exercised (in shares)	(485,016)		(1,163,374)	(1,429,756)
Cancelled/Forfeited (in shares)	(252,418)		(57,517)	(91,486)
Outstanding, ending balance (in shares)	3,956,364	4,218,278	5,170,976	5,120,293
Vested and exercisable (in shares)	2,905,712
Vested and expected to vest (in shares)	3,622,946
Weighted Average Exercise Price
Outstanding, beginning balance (in dollars per share)	$ 21.20	$ 14.28	$ 3.13
Granted (in dollars per share)	91.42		99.74	$ 39.01
Exercised (in dollars per share)	16.76		7.75	1.87
Cancelled/Forfeited (in dollars per share)	70.41		37.14	9.33
Outstanding, ending balance (in dollars per share)	27.04	$ 21.20	$ 14.28	$ 3.13
Vested and exercisable (in dollars per share)	14.20
Vested and expected to vest (in dollars per share)	$ 22.34
Weighted Average Remaining Contractual Life (Years)
Weighted average remaining contractual life, outstanding	5 years 10 months 24 days	6 years 7 months 6 days	7 years 6 months	7 years 3 months 18 days
Weighted average remaining contractual life, vested and exercisable	5 years
Weighted average remaining contractual life, vested and expected to vest	5 years 7 months 6 days
Aggregate Intrinsic Value
Outstanding, beginning balance	$ 443,595	$ 329,879	$ 81,371
Exercised	51,901		132,935	$ 121,591
Outstanding, ending balance	180,302	$ 443,595	$ 329,879	$ 81,371
Vested and exercisable	159,882
Vested and expected to vest	$ 178,657

Share-Based Compensation - Sc_3

Share-Based Compensation - Schedule of restricted stock and RSU activity (Details) - $ / shares	1 Months Ended	12 Months Ended
	Apr. 30, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restricted stock units
Number of Shares of Restricted Stock
Unvested, beginning balance (in shares)		275,989	149,004
Granted (in shares)		562,909	244,752
Vested/Released (in shares)		(120,599)	(99,970)
Cancelled/Forfeited (in shares)		(110,124)	(17,797)
Unvested, ending balance (in shares)		608,175	275,989	149,004
Weighted Average Grant Date Fair Value Per Share
Unvested, beginning balance (in dollars per share)		$ 114.99	$ 132.73
Granted (in dollars per share)		86	109.61
Vested/Released (in dollars per share)		123	127.71
Cancelled/Forfeited (in dollars per share)		0	0
Unvested, ending balance (in dollars per share)		$ 89	$ 114.99	$ 132.73
Restricted Stock
Number of Shares of Restricted Stock
Unvested, beginning balance (in shares)		12,184	88,988
Granted (in shares)	99,433	0	0
Vested/Released (in shares)		(12,184)	(76,804)
Cancelled/Forfeited (in shares)		0	0
Unvested, ending balance (in shares)		0	12,184	88,988
Weighted Average Remaining Contractual Life (Years)
Weighted Average Remaining Contractual Life, Unvested (Years)		0 years	3 months 18 days	1 year 2 months 12 days
Weighted Average Grant Date Fair Value Per Share
Unvested, beginning balance (in dollars per share)		$ 20.02	$ 19.49
Granted (in dollars per share)	$ 20.02	0	0
Vested/Released (in dollars per share)		20.02	19.97
Cancelled/Forfeited (in dollars per share)		0	0
Unvested, ending balance (in dollars per share)		$ 0	$ 20.02	$ 19.49

Commitments and Contingencies (

Commitments and Contingencies (Details)	Jan. 14, 2021USD ($)ft²renewal_option	Jun. 17, 2020defendant	May 27, 2020defendant	Mar. 18, 2020defendant	Mar. 16, 2020defendant	Jan. 27, 2020defendant	Jan. 24, 2020USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 22, 2020USD ($)
Loss Contingencies [Line Items]
Lease not yet commenced, term of contract	12 years
Lease not yet commenced, period preceding commencement	210 days
Number of renewal options, lease not yet commenced | renewal_option	2
Lease not yet commenced, renewal term	5 years
Lease not yet commenced, area (in sq feet) | ft²	281,110
Lease not yet commenced, building phase period	26 months
Lease not yet commenced, future minimum lease payments	$ 159,300,000
Lease not yet commenced, cost								$ 200,000	$ 0	$ 0
Escrow deposits related to lease not yet commenced								59,200,000
Investment agreement, expected amount								22,000,000
Investment agreement, amount advanced								20,000,000
Payments for investment in joint venture								11,000,000	0	0
Loss from investment in joint venture								2,977,000	$ 0	$ 0
Purchase commitments, due 2022								$ 52,900,000
Buildings
Loss Contingencies [Line Items]
Lease, initial term								8 years
Beyond Meat (Jiaxing) Food Co., Ltd.
Loss Contingencies [Line Items]
Lease, initial term											2 years
Letter of credit
Loss Contingencies [Line Items]
Maximum borrowing capacity	12,500,000							$ 12,500,000
Letter of credit | Fiscal quarter ending September 30, 2020
Loss Contingencies [Line Items]
Maximum borrowing capacity	6,300,000
Letter of credit | Fiscal quarters thereafter
Loss Contingencies [Line Items]
Maximum borrowing capacity	3,100,000
Letter of credit | Advance if no Event of Default, Based on Minimum Level of Gross Profit
Loss Contingencies [Line Items]
Maximum borrowing capacity	$ 0
JXEDZ
Loss Contingencies [Line Items]
Gain on investments								$ 1,100,000
Investment agreement, expected amount											$ 10,000,000
Investment agreement, land use right period								2 years
Investment agreement, additional amount to acquire land											$ 30,000,000
Former Co-manufacturer Complaint | Pending Litigation
Loss Contingencies [Line Items]
Damages sought, value							$ 628,689
Number of defendants | defendant						3
Securities Related Litigation | Pending Litigation
Loss Contingencies [Line Items]
Number of defendants | defendant		2	2	2	2
First Amended Complaint | Pending Litigation
Loss Contingencies [Line Items]
Accrued litigation liability								$ 515,000
Machinery and equipment
Loss Contingencies [Line Items]
Purchase order commitment term								12 months

Income Taxes - Schedule of comp

Income Taxes - Schedule of components of income tax expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current:
Federal	$ 0	$ 0	$ 0
State	60	72	9
Total current	60	72	9
Deferred:
Federal	0	0	0
State	0	0	0
Total deferred	0	0	0
Provision for income tax	$ 60	$ 72	$ 9

Income Taxes - Schedule of effe

Income Taxes - Schedule of effective income tax rate reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
U.S. income tax at federal statutory rate	$ (38,229)	$ (11,063)	$ (2,611)
State income tax, net of federal benefits	(4,991)	(1,962)	(2,550)
Foreign rate differential	(985)	(54)	0
Stock warrant liability	0	0	2,626
Share-based compensation	(4,932)	(21,007)	(21,236)
Research and development credits	(20)	(10)	(8)
Change in tax rates	(719)	2,989	73
Other	771	529	(98)
Change in valuation allowance	49,165	30,650	23,813
Provision for income tax	$ 60	$ 72	$ 9

Income Taxes - Schedule of defe

Income Taxes - Schedule of deferred tax assets and liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets:
Net operating loss (NOL)	$ 128,006	$ 78,464
Intangibles	1,308	1,495
Share-based compensation	4,584	3,295
Interest	388	311
Inventory reserve	2,139	2,262
Other	1,820	2,024
Total gross deferred tax assets	138,245	87,851
Deferred Tax liabilities:
Property, plant and equipment	3,056	1,773
Other	0	0
Total gross deferred tax liabilities	3,056	1,773
Valuation allowance	135,189	86,078
Net deferred tax assets (liabilities)	$ 0	$ 0

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Tax Credit Carryforward [Line Items]
Deferred tax assets, valuation allowance, percentage	100.00%
Valuation allowance	$ 135,189,000	$ 86,078,000
Increase in valuation allowance	49,100,000
Unrecognized tax benefits	8,861,000	5,399,000	$ 3,336,000
Unrecognized tax benefits that would impact effective tax rate	0	0
Research and development tax credits
Tax Credit Carryforward [Line Items]
Unrecognized tax benefits	8,000,000	4,900,000
Federal
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	514,100,000	344,200,000
Operating loss carryforwards, not subject to expiration	422,400,000
State
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	201,700,000	92,500,000
Foreign
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	$ 24,600,000	$ 1,300,000

Income Taxes - Schedule of unre

Income Taxes - Schedule of unrecognized tax benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Gross unrecognized tax benefits at the beginning of the year	$ 5,399	$ 3,336
Increases related to current year positions	3,462	2,063
Increases/Decreases related to prior year positions	0	0
Expiration of unrecognized tax benefits	0	0
Gross unrecognized tax benefits at the end of the year	$ 8,861	$ 5,399

Net Loss Per Share Available _3

Net Loss Per Share Available to Common Stockholders (“EPS”) - Narrative (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation	4,564,539	4,494,267	5,319,980
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation	3,956,364	4,218,278	5,170,976
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation	608,175	275,989

Net Loss Per Share Available _4

Net Loss Per Share Available to Common Stockholders (“EPS”) - Schedule of basic and diluted net loss per common share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Net loss	$ (182,105,000)	$ (52,752,000)	$ (12,443,000)
Undistributed net income available to unvested restricted stockholders	0	0	0
Net loss available to common stockholders—basic	(182,105,000)	(52,752,000)	(12,443,000)
Net loss available to common stockholders—diluted	$ (182,105,000)	$ (52,752,000)	$ (12,443,000)
Denominator:
Weighted average common shares outstanding—basic (in shares)	63,172,368	62,290,445	42,274,777
Dilutive effect of Notes, if converted (in shares)	0	0	0
Weighted average common shares outstanding—diluted (in shares)	63,172,368	62,290,445	42,274,777
Basic (in dollars per share)	$ (2.88)	$ (0.85)	$ (0.29)
Convertible Debt
Denominator:
Debt, outstanding balance	$ 1,150,000,000	$ 0
Options to purchase common stock
Denominator:
Dilutive effect (in shares)	0	0	0
Restricted stock units
Denominator:
Dilutive effect (in shares)	0	0	0
Common Stock
Denominator:
Dilutive effect (in shares)	0	0	0

Net Loss Per Share Available _5

Net Loss Per Share Available to Common Stockholders (“EPS”) - Schedule of antidilutive securities excluded from computation of earnings per share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,564,539	4,494,267	5,319,980
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,956,364	4,218,278	5,170,976
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	608,175	275,989	149,004